Monoclonal antibodies targeting GPC3 and antibody drug conjugates comprising such antibodies

CN119013305APending Publication Date: 2024-11-22FORESEEN TECHNOLOGY (BEIJING) CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380033927.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-24
Filing Date
2023-03-28
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

Existing cancer treatment methods are ineffective against the spread, metastasis and recurrence of malignant tumors. In particular, there is a lack of effective means for liver cancer and small cell lung cancer. Antibody drugs targeting GPC3 alone cannot significantly inhibit the growth of tumor cells.

Method used

Develop monoclonal antibodies and antibody-drug conjugates targeting GPC3. By designing antibodies containing specific variable region amino acid sequences, they can improve their binding and killing efficacy against GPC3 proteins. Antibody-drug conjugates can be combined with cytotoxins to enhance the effectiveness of the antibody-drug conjugates. tumor cell killing effect.

Benefits of technology

It achieves excellent binding and killing of tumor cells expressing GPC3 protein, significantly improves the therapeutic effect on liver cancer and small cell lung cancer, and provides a new diagnostic and prognostic tool.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000063_0000
    Figure 00000063_0000
  • Figure 00000063_0001
    Figure 00000063_0001
Patent Text Reader

Abstract

The invention provides a monoclonal antibody targeting GPC3 or an antigen binding fragment thereof, an antibody drug conjugate prepared from the monoclonal antibody, and a pharmaceutical composition or a diagnosis / prognosis composition containing the antibody drug conjugate. The antibody provided by the invention can be excellently combined with the GPC3 protein, and the antibody drug conjugate provided by the invention has a good killing effect on tumor cells expressing the GPC3 protein.
Need to check novelty before this filing date? Find Prior Art

Description

Monoclonal antibodies targeting GPC3 and antibody-drug conjugates containing the same

[0001] This application claims priority to Chinese patent application No. 202210435793.4, filed on April 24, 2022, entitled “Monoclonal antibodies targeting GPC3 and antibody-drug conjugates comprising the same”, the entire contents of which are incorporated herein by reference. Technical Field

[0002] The present invention relates to the field of biomedicine. Specifically, the present invention relates to a monoclonal antibody or an antigen-binding fragment thereof targeting GPC3, an antibody-drug conjugate comprising the antibody, and the use of the antibody and / or antibody-drug conjugate in treating related diseases. Background Art

[0003] Malignant tumors (cancer) have become the number one killer threatening the lives and health of people around the world. Over 14 million people worldwide develop cancer each year, and in my country alone, over 3 million new cancer patients are diagnosed each year.

[0004] The fundamental reason for the high mortality rate of cancer is the spread and metastasis of cancer cells, as well as the high incidence of recurrence and drug resistance in most patients after treatment. Existing clinical treatments—surgery, radiotherapy, and chemotherapy—are minimally effective or only offer short-term benefits for metastasis, recurrence, and drug resistance, failing to alter long-term survival. Currently, surgical resection is effective in approximately 10-20% of patients with early-stage cancer, but is virtually ineffective in patients with advanced metastatic disease. Radiotherapy can only treat localized lesions and is often used as an adjuvant therapy before or after surgery, or as a radical treatment for a few types of cancer. Chemotherapy can be used for patients with advanced metastatic disease, but due to significant side effects and the potential for developing both short-term and long-term drug resistance, it only offers significant short-term benefits in approximately 20-30% of patients. Even with combined treatments combining surgery, radiotherapy, and chemotherapy, the long-term survival rate over five years has hovered between 20-30%, and approximately 70-80% of patients die within five years of treatment due to metastasis, recurrence, and drug resistance. Even patients with early-stage cancer who present without metastasis still develop metastasis and relapse after treatment, leading to their death.

[0005] GPC3 is a tumor-associated antigen that is specifically overexpressed on tumor cells, particularly in patients with liver cancer and small cell lung cancer. Currently, effective treatments for these cancers are limited. The applicant has discovered that many antibody drugs targeting GPC3 alone do not significantly inhibit tumor cell growth. Therefore, the applicant hopes to develop a therapeutic approach using an antibody-drug conjugate for patients with GPC3-positive tumors.

[0006] Summary of the Invention

[0007] In one aspect, the present invention provides a monoclonal antibody or an antigen-binding fragment thereof targeting GPC3, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region,

[0008] The light chain variable region comprises:

[0009] VL CDR1 comprises the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 12,

[0010] VL CDR2 comprising the amino acid sequence shown in SEQ ID NO: 13 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 13, and

[0011] VL CDR3 comprising the amino acid sequence of SEQ ID NO: 14, or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted, or added relative to SEQ ID NO: 14;

[0012] and / or,

[0013] The heavy chain variable region comprises:

[0014] VH CDR1 comprising the amino acid sequence of SEQ ID NO: 32 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 32,

[0015] VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 33 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 33, and

[0016] VH CDR3 comprising the amino acid sequence of SEQ ID NO: 34 or comprising an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 34.

[0017] In another aspect, the present invention provides an antibody drug conjugate of the following formula:

[0018] Ab-LD, where:

[0019] The symbol "Ab" represents at least one of the aforementioned monoclonal antibodies of the present invention or an antigen-binding fragment thereof;

[0020] The symbol "L" represents a linker that connects the antibody portion and the partner molecule; and

[0021] The symbol "D" represents a partner molecule.

[0022] In another aspect, the present invention provides an antibody drug conjugate of the following formula, Ab-(LD)p, wherein:

[0023] The symbol "Ab" represents at least one of the aforementioned monoclonal antibodies of the present invention or an antigen-binding fragment thereof;

[0024] The symbol “L” represents a linker connecting the antibody portion and the partner molecule;

[0025] The symbol "D" represents a partner molecule; and

[0026] The symbol "p" represents the number of linker / partner molecules (preferably drug cargo) conjugated to the aforementioned portion of the monoclonal antibody or antigen-binding fragment thereof of the present invention.

[0027] In yet another aspect, the present invention provides a pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment thereof of the present invention or the antibody-drug conjugate of the present invention, and optionally a pharmaceutically acceptable carrier.

[0028] In another aspect, the present invention provides a diagnostic / prognostic composition comprising the monoclonal antibody or antigen-binding fragment thereof of the present invention or the antibody-drug conjugate of the present invention, and optionally a pharmaceutically acceptable carrier.

[0029] In yet another aspect, the present invention provides an isolated nucleic acid molecule encoding the monoclonal antibody or antigen-binding fragment thereof of the present invention.

[0030] In yet another aspect, the present invention provides an expression vector comprising the nucleic acid molecule of the present invention.

[0031] In another aspect, the present invention provides a host cell comprising the nucleic acid molecule of the present invention or the expression vector of the present invention.

[0032] In yet another aspect, the present invention provides a hybridoma cell that expresses a monoclonal antibody or antigen-binding fragment thereof of the present invention.

[0033] In another aspect, the present invention provides use of the monoclonal antibody or antigen-binding fragment thereof of the present invention or the antibody-drug conjugate of the present invention in preparing a pharmaceutical composition; optionally, the pharmaceutical composition is used to treat malignant tumors, prevent and / or treat malignant tumor metastasis or recurrence in patients.

[0034] In another aspect, the present invention provides a method for treating a malignant tumor, preventing and / or treating metastasis or recurrence of a malignant tumor in a patient, the method comprising administering to the patient an effective amount of the monoclonal antibody or antigen-binding fragment thereof of the present invention, the antibody-drug conjugate of the present invention, or the pharmaceutical composition of the present invention.

[0035] In another aspect, the present invention provides use of the monoclonal antibody or antigen-binding fragment thereof of the present invention or the antibody-drug conjugate of the present invention in the preparation of a diagnostic / prognostic composition; optionally, the diagnostic / prognostic composition is used to detect the presence of a malignant tumor in a patient; optionally, the diagnostic / prognostic composition is used to prognose the recurrence or progression of a malignant tumor in a patient.

[0036] In yet another aspect, the present invention provides a method for prognosing recurrence or progression of a malignant tumor in a patient, the method comprising:

[0037] (a) isolating a biological sample comprising tumor cells from the patient;

[0038] (b) contacting the biological sample containing tumor cells with the monoclonal antibody or antigen-binding fragment thereof of the present invention or the antibody drug conjugate of the present invention; and

[0039] (c) identifying the presence of tumor cells that bind to the monoclonal antibody or antigen-binding fragment thereof,

[0040] The recurrence or progression of the malignancy in said patient is thereby prognosed.

[0041] In yet another aspect, the present invention provides a method for detecting / diagnosing the presence of a malignant tumor in a patient, comprising:

[0042] a) contacting a biological sample obtained from the patient with the monoclonal antibody or antigen-binding fragment thereof of the present invention or the antibody drug conjugate of the present invention;

[0043] b) detecting binding of the monoclonal antibody or antigen-binding fragment thereof to a target antigen in the biological sample, wherein detection of the binding indicates the presence of a malignant tumor in the patient.

[0044] In another aspect, the present invention provides a method for detecting the presence of tumor cells in a biological sample, comprising:

[0045] a) contacting the biological sample with the monoclonal antibody or antigen-binding fragment thereof of the present invention or the antibody-drug conjugate of the present invention;

[0046] b) detecting the binding of the monoclonal antibody or antigen-binding fragment thereof or the antibody drug conjugate to the target antigen in the biological sample,

[0047] Detection of the binding indicates the presence of tumor cells in the biological sample.

[0048] In another aspect, the present invention provides a method for isolating tumor cells, comprising:

[0049] (a) providing a cell population suspected of containing tumor cells;

[0050] (b) identifying a subpopulation of cells that binds to the monoclonal antibody or antigen-binding fragment thereof or the antibody drug conjugate of the present invention; and

[0051] (c) isolating the subpopulation.

[0052] In another aspect, the present invention provides a method for producing a monoclonal antibody or an antigen-binding fragment thereof targeting human tumor cells expressing GPC3, comprising:

[0053] (i) culturing the host cell of the present invention under conditions suitable for expression of the nucleic acid molecule or expression vector, and

[0054] (ii) isolating and purifying the antibody or antigen-binding fragment thereof expressed by the nucleic acid molecule or expression vector.

[0055] The antibodies of the present invention have excellent binding to the GPC3 protein and can bind to tumor cells expressing GPC3, particularly liver cancer cells and small cell lung cancer cells. The antibody-drug conjugates of the present invention have excellent killing effects on tumor cells expressing GPC3, particularly liver cancer cells and small cell lung cancer cells. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1 EC50 of GPC3 antibody binding to HepG2 cells detected by flow cytometry;

[0057] FIG2 is the median fluorescence intensity (max MFI) of GPC3 antibody binding to HepG2 cells at the maximum antibody concentration detected by flow cytometry.

[0058] Sequence Description:

[0059] SEQ ID NO: 1: Chimeric murine antibody light chain coding sequence (FS001-mVL-LC (kappa))

[0060] SEQ ID NO: 2: Humanized antibody light chain coding sequence (FS001-VL1-LC (kappa))

[0061] SEQ ID NO: 3: Humanized antibody light chain coding sequence (FS001-VL2-LC (kappa))

[0062] SEQ ID NO: 4: Humanized antibody light chain coding sequence (FS001-VL3-LC (kappa))

[0063] SEQ ID NO: 5: Humanized antibody light chain coding sequence (FS001-VL4-LC (kappa))

[0064] SEQ ID NO:6: Chimeric murine antibody heavy chain coding sequence (FS001-mVH-HC(IgG1))

[0065] SEQ ID NO: 7: Humanized antibody heavy chain coding sequence (FS001-VH1-HC (IgG1))

[0066] SEQ ID NO: 8: Humanized antibody heavy chain coding sequence (FS001-VH2-HC (IgG1))

[0067] SEQ ID NO: 9: Humanized antibody heavy chain coding sequence (FS001-VH3-HC (IgG1))

[0068] SEQ ID NO: 10: Humanized antibody heavy chain coding sequence (FS001-VH4-HC (IgG1))

[0069] SEQ ID NO: 11: Mouse antibody light chain variable region (FS001-mVL)

[0070] SEQ ID NO:12: CDR1 of FS001-mVL (mVL-CDR1)

[0071] SEQ ID NO:13: CDR2 of FS001-mVL (mVL-CDR2)

[0072] SEQ ID NO:14: CDR3 of FS001-mVL (mVL-CDR3)

[0073] SEQ ID NO: 15: Humanized light chain variable region (FS001-VL1)

[0074] SEQ ID NO: 16: CDR1 of FS001-VL1 (VL1-CDR1)

[0075] SEQ ID NO: 17: CDR2 of FS001-VL1 (VL1-CDR2)

[0076] SEQ ID NO: 18: CDR3 of FS001-VL1 (VL1-CDR3)

[0077] SEQ ID NO: 19: Humanized light chain variable region (FS001-VL2)

[0078] SEQ ID NO: 20: CDR1 of FS001-VL2 (VL2-CDR1)

[0079] SEQ ID NO: 21: CDR2 of FS001-VL2 (VL2-CDR2)

[0080] SEQ ID NO: 22: CDR3 of FS001-VL2 (VL2-CDR3)

[0081] SEQ ID NO: 23: Humanized light chain variable region (FS001-VL3)

[0082] SEQ ID NO: 24: CDR1 of FS001-VL3 (VL3-CDR1)

[0083] SEQ ID NO:25: CDR2 of FS001-VL3 (VL3-CDR2)

[0084] SEQ ID NO:26: CDR3 of FS001-VL3 (VL3-CDR3)

[0085] SEQ ID NO: 27: Humanized light chain variable region (FS001-VL4)

[0086] SEQ ID NO: 28: CDR1 of FS001-VL4 (VL4-CDR1)

[0087] SEQ ID NO: 29: CDR2 of FS001-VL4 (VL4-CDR2)

[0088] SEQ ID NO:30: CDR3 of FS001-VL4 (VL4-CDR3)

[0089] SEQ ID NO: 31: Murine antibody heavy chain variable region (FS001-mVH)

[0090] SEQ ID NO:32: CDR1 of FS001-mVH (mVH-CDR1)

[0091] SEQ ID NO:33: CDR2 of FS001-mVH (mVH-CDR2)

[0092] SEQ ID NO:34: CDR3 of FS001-mVH (mVH-CDR3)

[0093] SEQ ID NO: 35: Humanized heavy chain variable region (FS001-VH1)

[0094] SEQ ID NO:36: CDR1 of FS001-VH1 (VH1-CDR1)

[0095] SEQ ID NO:37: CDR2 of FS001-VH1 (VH1-CDR2)

[0096] SEQ ID NO:38: CDR3 of FS001-VH1 (VH1-CDR3)

[0097] SEQ ID NO: 39: Humanized heavy chain variable region (FS001-VH2)

[0098] SEQ ID NO:40: CDR1 of FS001-VH2 (VH2-CDR1)

[0099] SEQ ID NO:41: CDR2 of FS001-VH2 (VH2-CDR2)

[0100] SEQ ID NO:42: CDR3 of FS001-VH2 (VH2-CDR3)

[0101] SEQ ID NO: 43: Humanized heavy chain variable region (FS001-VH3)

[0102] SEQ ID NO:44: CDR1 of FS001-VH3 (VH3-CDR1)

[0103] SEQ ID NO:45: CDR2 of FS001-VH3 (VH3-CDR2)

[0104] SEQ ID NO:46: CDR3 of FS001-VH3 (VH3-CDR3)

[0105] SEQ ID NO: 47: Humanized heavy chain variable region (FS001-VH4)

[0106] SEQ ID NO:48: CDR1 of FS001-VH4 (VH4-CDR1)

[0107] SEQ ID NO:49: CDR2 of FS001-VH4 (VH4-CDR2)

[0108] SEQ ID NO:50: CDR3 of FS001-VH4 (VH4-CDR3)

[0109] SEQ ID NO: 51: Human light chain constant region

[0110] SEQ ID NO: 52: Human heavy chain constant region

[0111] SEQ ID NO: 53: Murine antibody light chain variable region + human light chain constant region (FS001-mVL-LC (kappa))

[0112] SEQ ID NO: 54: Humanized light chain variable region + human light chain constant region (FS001-VL1-LC (kappa))

[0113] SEQ ID NO: 55: Humanized light chain variable region + human light chain constant region (FS001-VL2-LC (kappa))

[0114] SEQ ID NO: 56: Humanized light chain variable region + human light chain constant region (FS001-VL3-LC (kappa))

[0115] SEQ ID NO: 57: Humanized light chain variable region + human light chain constant region (FS001-VL4-LC (kappa))

[0116] SEQ ID NO: 58: Murine antibody heavy chain variable region + human heavy chain constant region (FS001-mVH-HC (IgG1))

[0117] SEQ ID NO: 59: Humanized heavy chain variable region + human heavy chain constant region (FS001-VH1-HC(IgG1))

[0118] SEQ ID NO: 60: Humanized heavy chain variable region + human heavy chain constant region (FS001-VH2-HC (IgG1))

[0119] SEQ ID NO: 61: Humanized heavy chain variable region + human heavy chain constant region (FS001-VH3-HC (IgG1))

[0120] SEQ ID NO: 62: Humanized heavy chain variable region + human heavy chain constant region (FS001-VH4-HC (IgG1))

[0121] SEQ ID NO: 63: CDR1 of the murine antibody light chain variable region (or humanized light chain variable region)

[0122] SEQ ID NO: 64: CDR2 of murine antibody heavy chain variable region (or humanized heavy chain variable region) DETAILED DESCRIPTION

[0123] (1) General definition

[0124] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, terms and laboratory procedures related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, and immunology used herein are those widely used in the respective fields and are standard procedures. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.

[0125] As used herein, "antibody" refers to immunoglobulins and immunoglobulin fragments, whether natural or partially or completely synthetically (e.g., recombinantly), including any fragment thereof that retains the binding specificity of a full-length immunoglobulin comprising at least a portion of the variable region of an immunoglobulin molecule. Thus, antibodies include any protein having a binding domain that is homologous or substantially homologous to an immunoglobulin antigen-binding domain (antibody binding site). Antibodies include antibody fragments, such as anti-tumor stem cell antibody fragments. As used herein, the term antibody includes synthetic antibodies, recombinantly produced antibodies, multispecific antibodies (e.g., bispecific antibodies), human antibodies, non-human antibodies, humanized antibodies, chimeric antibodies, intrabodies, and antibody fragments, such as, but not limited to, Fab fragments, Fab' fragments, F(ab')2 fragments, Fv fragments, disulfide-linked Fv (dsFv), Fd fragments, Fd' fragments, single-chain Fv (scFv), single-chain Fab (scFab), diabodies, anti-idiotypic (anti-Id) antibodies, or antigen-binding fragments of any of the above antibodies. The antibodies provided herein include members of any immunoglobulin class (e.g., IgG, IgM, IgD, IgE, IgA, and IgY), any class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass (e.g., IgG2a and IgG2b).

[0126] As used herein, an "antibody fragment" or "antigen-binding fragment" of an antibody refers to any portion of a full-length antibody that is less than full-length but contains at least a portion of the variable region of the antibody that binds to an antigen (e.g., one or more CDRs and / or one or more antibody binding sites) and thus retains binding specificity and at least part of the specific binding ability of the full-length antibody. Thus, an antigen-binding fragment refers to an antibody fragment that contains an antigen-binding portion that binds to the same antigen as the antibody from which the antibody fragment was derived. Antibody fragments include antibody derivatives produced by enzymatic treatment of full-length antibodies, as well as synthetically produced derivatives, such as recombinantly produced derivatives. Antibodies include antibody fragments. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, single-chain Fv (scFv), Fv, dsFv, diabodies, Fd and Fd' fragments, and other fragments, including modified fragments (see, e.g., Methods in Molecular Biology, Vol 207: Recombinant Antibodies for Cancer Therapy Methods and Protocols (2003); Chapter 1; p 3-25, Kipriyanov). The fragments may comprise multiple chains linked together, for example, by disulfide bonds and / or by peptide linkers. Antibody fragments generally contain at least or about 50 amino acids, and typically at least or about 200 amino acids. Antigen-binding fragments include any antibody fragment that, when inserted into an antibody framework (e.g., by replacing the corresponding region), obtains immunospecific binding (i.e., exhibits at least or at least about 10 7 -10 8 M -1 Antibodies to the Ka) antigen.

[0127] As used herein, "monoclonal antibody" refers to a population of identical antibodies, meaning that each individual antibody molecule in the monoclonal antibody population is identical to other antibody molecules. This characteristic is in contrast to the characteristic of a polyclonal population of antibodies, which comprises antibodies with a variety of different sequences. Monoclonal antibodies can be prepared by many well-known methods (Smith et al. (2004) J. Clin. Pathol. 57, 912-917; and Nelson et al., J Clin Pathol (2000), 53, 111-117). For example, monoclonal antibodies can be prepared by immortalized B cells, for example, by fusion with myeloma cells to produce hybridoma cell lines or by infecting B cells with viruses such as EBV. Recombinant technology can also be used to prepare antibodies from a clonal population of host cells in vitro by transforming host cells with a plasmid carrying an artificial sequence of nucleotides encoding the antibody.

[0128] As used herein, the term "hybridoma" or "hybridoma cell" refers to a cell or cell line (usually a myeloma or lymphoma cell) produced by the fusion of an antibody-producing lymphocyte and a non-antibody-producing cancer cell. As known to those of ordinary skill in the art, hybridomas can proliferate and continuously produce a specific monoclonal antibody. Methods for producing hybridomas are known in the art (see, for example, Harlow & Lane, 1988). When referring to the term "hybridoma" or "hybridoma cell," it also includes subclones and progeny cells of the hybridoma.

[0129] As used herein, a "conventional antibody" refers to an antibody comprising two heavy chains (which may be designated H and H') and two light chains (which may be designated L and L'), and two antigen-binding sites, wherein each heavy chain may be a full-length immunoglobulin heavy chain or any functional region thereof that retains antigen-binding ability (e.g., heavy chains include but are not limited to V and L'). H Chain, V H -C H 1 chain and V H -C H 1-C H 2-C H 3 chains), and each light chain can be a full-length light chain or any functional region (e.g., a light chain including but not limited to V L Chain and V L -C L Each heavy chain (H and H') is paired with a light chain (L and L', respectively).

[0130] As used herein, a full-length antibody is one having two full-length heavy chains (e.g., V H -C H 1-C H 2-C H 3 or V H -C H 1-C H 2-C H 3-C H 4) and two full-length light chains (V L -C L ) and hinge regions, such as antibodies naturally produced by antibody-secreting B cells and synthetically produced antibodies having the same domains.

[0131] As used herein, dsFv refers to a fragment having a stable V H -V L Fv with engineered intermolecular disulfide bonds.

[0132] As used herein, a Fab fragment is an antibody fragment obtained by digesting a full-length immunoglobulin with papain, or a fragment having the same structure, for example, produced by recombinant synthesis. Land C L ) and another chain comprising the variable domain of the heavy chain (V H ) and a constant region domain of the heavy chain (C H 1).

[0133] As used herein, a F(ab')2 fragment is an antibody fragment resulting from pepsin digestion of an immunoglobulin at pH 4.0-4.5, or a fragment having the same structure produced synthetically, for example, by recombinant methods. A F(ab')2 fragment essentially comprises two Fab fragments, each heavy chain portion of which contains several additional amino acids, including cysteine, which forms a disulfide bond linking the two fragments.

[0134] As used herein, a Fab' fragment is a fragment comprising half (one heavy chain and one light chain) of a F(ab')2 fragment.

[0135] As used herein, a scFv fragment refers to a fragment comprising variable light chains (V L ) and variable heavy chain (V H The length of the linker is such that the two variable domains are bridged without substantial interference. An exemplary linker is (Gly-Ser) with some Glu or Lys residues interspersed to increase solubility. n residue.

[0136] The term "chimeric antibody" refers to antibodies in which the variable region sequences are derived from one species and the constant region sequences are derived from another species, such as antibodies in which the variable region sequences are derived from a mouse antibody and the constant region sequences are derived from a human antibody.

[0137] "Humanized" antibodies refer to non-human (e.g., mouse) antibody forms that are chimeric immunoglobulins, immunoglobulin chains, or fragments thereof (e.g., Fv, Fab, Fab', F(ab')2, or other antigen-binding subsequences of antibodies) that contain minimal sequence derived from non-human immunoglobulin. Preferably, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementarity determining region (CDR) of the recipient antibody are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, or rabbit having the desired specificity, affinity, and capacity.

[0138] In addition, in humanization, it is also possible to mutate the amino acid residues in the CDR1, CDR2 and / or CDR3 regions of VH and / or VL to thereby improve one or more binding properties (e.g., affinity) of the antibody. For example, PCR-mediated mutations can be used to introduce mutations, and their impact on antibody binding or other functional properties can be evaluated using in vitro or in vivo tests as described herein. Typically, conservative mutations are introduced. Such mutations can be amino acid substitutions, additions, or deletions. In addition, the mutations in the CDRs are typically no more than one or two. Therefore, the humanized antibodies of the present invention also encompass antibodies comprising one or two amino acid mutations in the CDRs.

[0139] As used herein, the term "epitope" refers to any antigenic determinant on an antigen to which the paratope of an antibody binds. Epitopic determinants typically comprise chemically active surface patterns of molecules, such as amino acids or sugar side chains, and typically have specific three-dimensional structural characteristics as well as specific charge characteristics.

[0140] As used herein, a variable domain or variable region is a specific Ig domain of an antibody heavy or light chain that contains an amino acid sequence that varies between different antibodies. Each light chain and each heavy chain has one variable region domain, V L and V H The variable domain provides antigen specificity and is therefore responsible for antigen recognition. Each variable region comprises CDRs, which are part of the antigen binding site domain, and framework regions (FRs).

[0141] As used herein, "antigen binding domain" and "antigen-binding site" are used synonymously to refer to the domain within an antibody that recognizes and physically interacts with a cognate antigen. A natural, conventional full-length antibody molecule has two conventional antigen-binding sites, each comprising a heavy chain variable region portion and a light chain variable region portion. A conventional antigen-binding site comprises loops connecting antiparallel beta chains within the variable region domain. An antigen-binding site may comprise other portions of the variable region domain. Each conventional antigen-binding site comprises three hypervariable regions from the heavy chain and three hypervariable regions from the light chain. Hypervariable regions are also referred to as complementarity determining regions (CDRs).

[0142] As used herein, "hypervariable region," "HV," "complementarity determining region," "CDR," and "antibody CDR" are used interchangeably to refer to one of the multiple portions within each variable region that together form the antigen binding site of an antibody. Each variable region domain comprises three CDRs, designated CDR1, CDR2, and CDR3. For example, the light chain variable region domain comprises three CDRs, designated VL CDR1, VL CDR2, and VL CDR3; the heavy chain variable region domain comprises three CDRs, designated VH CDR1, VH CDR2, and VH CDR3. The three CDRs in the variable region are discontinuous along the linear amino acid sequence, but are proximal in the folded polypeptide. The CDRs are located within loops connecting the parallel strands of the beta sheet of the variable domain. As described herein, one of skill in the art knows and can identify CDRs based on Kabat or Chothia numbering (see, e.g., Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242, and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917).

[0143] As used herein, framework regions (FRs) are domains within the antibody variable region domains that are located within the beta sheets; in terms of amino acid sequence, FR regions are relatively more conserved than hypervariable regions.

[0144] As used herein, a "constant region" domain is a domain in an antibody heavy or light chain that comprises an amino acid sequence that is relatively more conserved than the amino acid sequence of the variable region domain. In a conventional full-length antibody molecule, each light chain has a single light chain constant region (C L ) domain, and each heavy chain comprises one or more heavy chain constant regions (C H ) domain, including C H 1. C H 2. C H 3 and C H 4. Full-length IgA, IgD, and IgG isotypes contain C H 1. C H 2. C H 3 and hinge regions, while IgE and IgM contain C H 1. C H 2. C H 3 and C H 4. C H 1 and C LThe domains extend the Fab arms of the antibody molecule, thereby assisting in interacting with the antigen and rotating the antibody arms. The antibody constant region can serve effector functions such as, but not limited to, clearing the antigen, pathogen, and toxin to which the antibody specifically binds, for example, by interacting with various cells, biomolecules, and tissues.

[0145] As used herein, a functional region of an antibody is a region comprising at least V H 、V L 、C H (For example, C H 1. C H 2 or C H 3) C L or the hinge region domain or at least the functional region thereof.

[0146] As used herein, V H The functional area of ​​the domain is to retain the complete V H at least part of the binding specificity of the V H One or more CDRs of the structural domain) H domain, so that the V H The functional region of the antibody domain alone or in combination with another antibody domain (e.g., V L domain) or a combination of regions thereof that bind to an antigen. H The functional region of the domain is the V H The regions of CDR1, CDR2 and / or CDR3 of the domain.

[0147] As used herein, V L The functional area of ​​the domain is to retain the complete V L at least part of the binding specificity of the V L One or more CDRs of the structural domain) L domain, so that the V L The functional region of the antibody domain alone or in combination with another antibody domain (e.g., V H domain) or a combination of regions thereof that bind to an antigen. L The functional region of the domain is the V L The regions of CDR1, CDR2 and / or CDR3 of the domain.

[0148] As used herein, "specifically binds" or "immunospecifically binds" with respect to an antibody or antigen-binding fragment thereof are used interchangeably herein and refer to the ability of an antibody or antigen-binding fragment to form one or more non-covalent bonds with the same antigen through non-covalent interactions between the antibody combining sites of the antibody and the antigen. The antigen can be an isolated antigen or present on a tumor cell.

[0149] As used herein, the terms "Kassoc" or "Ka" are intended to refer to the association rate of a particular antibody-antigen interaction, while the terms "Kdis" or "Kd" are intended to refer to the dissociation rate of a particular antibody-antigen interaction. As used herein, the term "KD" is intended to refer to the dissociation constant, which is obtained by the ratio of Kd to Ka (i.e., Kd / Ka) and is expressed as a molar concentration (M). The KD value of an antibody can be determined using methods known in the art. The method for determining the KD of an antibody can be, for example, surface plasmon resonance (SPR) (Rich and Myszka (2000) Curr. Opin. Biotechnol 11:54; Englebienne (1998) Analyst. 123:1599), isothermal titration calorimetry (ITC), or other kinetic interaction assays known in the art (see, e.g., Paul, ed., Fundamental Immunology, 2nd ed., Raven Press, New York, pages 332-336 (1989); see also U.S. Pat. No. 7,229,619 describing exemplary SPR and ITC methods for calculating the binding affinity of an antibody). Instruments and methods for real-time detection and monitoring of binding rates are known and commercially available (see, BiaCore 2000, Biacore AB, Upsala, Sweden and GE Healthcare Life Sciences; Malmqvist (2000) Biochem. Soc. Trans. 27:335).

[0150] As used herein, the term "conservative sequence modifications" or "conservative amino acid modifications" or "conservative amino acid substitutions" refers to amino acid modifications that do not significantly affect or alter the binding properties of an antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the antibodies of the present invention by standard techniques well known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. "Conservative amino acid modifications" or "conservative amino acid substitutions" are substitutions in which an amino acid residue is replaced with an amino acid residue having similar properties and / or structure. Families of amino acid residues with similar side chains have been defined in the art.

[0151] There are 20 common amino acids, which can be classified in many ways. For example, amino acids can be classified based on their binding groups into aliphatic, aromatic, heterocyclic, sulfur-containing, and iodine-containing amino acids. Aliphatic amino acids include alanine, valine, leucine, isoleucine, methionine, aspartic acid, glutamic acid, lysine, arginine, glycine, serine, threonine, cysteine, asparagine, and glutamine. Aromatic amino acids include phenylalanine and tyrosine. Heterocyclic amino acids include histidine and tryptophan. Heterocyclic imino acids include proline. Amino acids can be classified based on their chemical properties into acidic, basic, and neutral amino acids. Neutral amino acids include glycine, alanine, leucine, isoleucine, valine, cystine, cysteine, methionine, threonine, serine, phenylalanine, tyrosine, tryptophan, proline, methionine, and hydroxyproline. Acidic amino acids include glutamic acid and aspartic acid. Basic amino acids include lysine, arginine, and histidine.

[0152] Additionally, amino acids can be further classified as follows: amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0153] As used herein, "polypeptide" refers to two or more amino acids covalently linked. The terms "polypeptide" and "protein" are used interchangeably herein.

[0154] An "isolated protein," "isolated polypeptide," or "isolated antibody" means that the protein, polypeptide, or antibody is (1) not associated with naturally associated components that accompany it in its native state, (2) free of other proteins from the same species, (3) expressed by cells from a different species, or (4) not occurring in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cells from which the polypeptide originates would be "isolated" from its naturally associated components. A protein can also be rendered substantially free of naturally associated components by isolation, i.e., using protein purification techniques well known in the art.

[0155] "Substitution", "deletion" or "addition" of an amino acid residue refers to a conservative amino acid modification in a peptide or protein that does not alter the function and / or biological activity of the peptide or protein. For example, the substitution of an amino acid residue can be a conservative amino acid substitution. Suitable conservative amino acid substitutions are known to those skilled in the art and can generally be made without altering the biological activity of the resulting molecule. Generally, those skilled in the art recognize that single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, for example, Watson et al., Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin / Cummings Pub.co., p. 224).

[0156] As used herein, the terms "polynucleotide" and "nucleic acid molecule" refer to an oligomer or polymer comprising at least two linked nucleotides or nucleotide derivatives, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), usually linked together by phosphodiester bonds.

[0157] As used herein, isolated nucleic acid molecules are nucleic acid molecules isolated from other nucleic acid molecules present in the natural origin of nucleic acid molecules. " Isolated " nucleic acid molecules such as cDNA molecules can be substantially free of other cellular materials or culture medium when prepared by recombinant technology, or substantially free of chemical precursors or other chemical compositions when chemosynthesis. The exemplary isolated nucleic acid molecules provided herein comprise the isolated nucleic acid molecules of the antibody or Fab provided by coding.

[0158] Sequence "identity" has a meaning recognized in the art, and the percentage of sequence identity between two nucleic acid or polypeptide molecules or regions can be calculated using published techniques. Sequence identity can be measured along the entire length of a polynucleotide or polypeptide or along a region of the molecule. (See, for example: Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). While there are many methods to measure the identity between two polynucleotides or polypeptides, the term "identity" is well known to those of skill in the art (Carrillo, H. & Lipman, D., SIAM J Applied Math 48: 1073 (1988)).

[0159] As used herein, "operably linked" with respect to nucleic acid sequences, regions, elements, or domains means that the nucleic acid regions are functionally related to each other. For example, a promoter can be operably linked to a nucleic acid encoding a polypeptide such that the promoter regulates or mediates transcription of the nucleic acid.

[0160] As used herein, "expression" refers to the process of producing a polypeptide through transcription and translation of a polynucleotide. The expression level of a polypeptide can be assessed using any method known in the art, including, for example, methods for measuring the amount of polypeptide produced by a host cell. Such methods may include, but are not limited to, quantification of polypeptides in cell lysates by ELISA, gel electrophoresis followed by Coomassie blue staining, Lowry protein assay, and Bradford protein assay.

[0161] As used herein, a "host cell" is a cell that is used to receive, maintain, replicate, and amplify a vector. Host cells can also be used to express polypeptides encoded by the vector. When the host cell divides, the nucleic acid contained in the vector replicates, thereby amplifying the nucleic acid. The host cell can be a eukaryotic cell or a prokaryotic cell. Suitable host cells include, but are not limited to, CHO cells, various COS cells, HeLa cells, and HEK cells, such as HEK 293 cells.

[0162] As used herein, a "vector" is a replicable nucleic acid that, when transformed into an appropriate host cell, can express one or more heterologous proteins from the vector. Vectors include those into which nucleic acids encoding polypeptides or fragments thereof can be introduced, typically by restriction digestion and ligation. Vectors also include those that contain nucleic acids encoding polypeptides. Vectors are used to introduce nucleic acids encoding polypeptides into host cells for the purpose of amplifying nucleic acids or for expressing / displaying polypeptides encoded by nucleic acids. Vectors are typically kept episomal, but can be designed to integrate genes or portions thereof into chromosomes of the genome. Artificial chromosome vectors, such as yeast artificial vectors and mammalian artificial chromosomes, are also contemplated. The selection and use of such vectors are well known to those skilled in the art.

[0163] As used herein, "expression vector" includes a vector capable of expressing DNA that is operably linked to a regulatory sequence such as a promoter region that can affect the expression of such DNA fragments. Such additional fragments may include promoter and terminator sequences, and may optionally include one or more origins of replication, one or more selection markers, enhancers, polyadenylation signals, etc. Expression vectors are generally derived from plasmid or viral DNA, or may contain elements of both. Therefore, an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, phage, recombinant virus or other vector, which, when introduced into an appropriate host cell, results in the expression of the cloned DNA. Suitable expression vectors are well known to those skilled in the art and include expression vectors that are replicable in eukaryotic cells and / or prokaryotic cells, as well as expression vectors that remain episomal or that are integrated into the host cell genome.

[0164] As used herein, "treating" an individual suffering from a disease or condition means that the individual's symptoms are partially or completely alleviated, or remain unchanged after treatment. Thus, treatment includes prevention, treatment, and / or cure. Prevention refers to preventing the underlying disease and / or preventing the worsening of symptoms or progression of the disease. Treatment also includes any pharmaceutical use of any of the antibodies or antigen-binding fragments thereof provided, as well as the compositions provided herein.

[0165] As used herein, "therapeutic effect" refers to an effect resulting from treatment of a subject that alters, typically ameliorates or improves the symptoms of a disease or condition, or cures the disease or condition.

[0166] As used herein, "therapeutically effective amount" or "therapeutically effective dose" refers to an amount of a substance, compound, material, or composition comprising a compound that is at least sufficient to produce a therapeutic effect after administration to a subject. Thus, it is the amount necessary to prevent, cure, ameliorate, arrest, or partially arrest the symptoms of a disease or condition.

[0167] As used herein, a "prophylactically effective amount" or "prophylactically effective dose" refers to an amount of a substance, compound, material, or composition comprising a compound that, when administered to a subject, will have the desired prophylactic effect, e.g., preventing or delaying the onset or recurrence of a disease or symptom, or reducing the likelihood of the onset or recurrence of a disease or symptom. A fully prophylactically effective dose need not occur by administering one dose, and may occur only after administering a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations.

[0168] As used herein, the term "patient" refers to a mammal, such as a human.

[0169] (II) Antibodies targeting GPC3 protein

[0170] In one aspect, the present invention provides a monoclonal antibody or an antigen-binding fragment thereof targeting GPC3, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region,

[0171] The light chain variable region comprises:

[0172] VL CDR1 comprises the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 12,

[0173] VL CDR2 comprising the amino acid sequence shown in SEQ ID NO: 13 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 13, and

[0174] VL CDR3 comprising the amino acid sequence of SEQ ID NO: 14, or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted, or added relative to SEQ ID NO: 14;

[0175] and / or,

[0176] The heavy chain variable region comprises:

[0177] VH CDR1 comprising the amino acid sequence of SEQ ID NO: 32 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 32,

[0178] VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 33 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 33, and

[0179] VH CDR3 comprising the amino acid sequence of SEQ ID NO: 34 or comprising an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 34.

[0180] GPC3 stands for Glypican-3. Human GPC3 is identified in the Uniprot database as P51654 (see https: / / www.uniprot.org / uniprot / P51654). GPC3 is a tumor-associated antigen that is specifically overexpressed in tumor cells, particularly in patients with liver cancer and small cell lung cancer.

[0181] Targeting the potential GPC3 protein, the inventors designed chimeric antibodies using murine light / heavy chain variable regions and human light / heavy chain constant regions, as well as various humanized antibody variants. Experiments shown in Figures 1 and 2 demonstrate that the EC50 and maximum MFI binding abilities of several monoclonal antibodies of the present invention on HepG2 cells are superior to those of the positive control antibody, codrituzumab. Leveraging the superior binding abilities of the monoclonal antibodies of the present invention, partner molecules, such as cytotoxins, can be effectively delivered to tumor cells.

[0182] In some embodiments, the VL CDR1 comprises the amino acid sequence of SEQ ID NO: 12 or has 1 or 2 amino acid residue substitutions relative to SEQ ID NO: 12. In some embodiments, the VL CDR2 comprises the amino acid sequence of SEQ ID NO: 13 or has 1 or 2 amino acid residue substitutions relative to SEQ ID NO: 13. In some embodiments, the VL CDR3 comprises the amino acid sequence of SEQ ID NO: 14 or has 1 or 2 amino acid residue substitutions relative to SEQ ID NO: 14. In some embodiments, the amino acid substitutions are conservative amino acid substitutions that do not alter the function and / or activity of the amino acid sequence.

[0183] In some embodiments, the VH CDR1 comprises the amino acid sequence of SEQ ID NO: 32 or has 1 or 2 amino acid residue substitutions relative to SEQ ID NO: 32. In some embodiments, the VH CDR2 comprises the amino acid sequence of SEQ ID NO: 33 or has 1 or 2 amino acid residue substitutions relative to SEQ ID NO: 33. In some embodiments, the VH CDR3 comprises the amino acid sequence of SEQ ID NO: 34 or has 1 or 2 amino acid residue substitutions relative to SEQ ID NO: 34. In some embodiments, the amino acid substitutions are conservative amino acid substitutions that do not alter the function and / or activity of the amino acid sequence.

[0184] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the invention comprises a light chain variable region comprising VL CDR1, VL CDR2, and VL CDR3.

[0185] In some embodiments, the VL CDR1 comprises or consists of the amino acid sequence shown in X1SSQSLVHSNGNTYLQ (SEQ ID NO: 63), wherein the symbol X1 represents:

[0186] - aliphatic amino acids;

[0187] - any one of the following amino acids: alanine, valine, leucine, isoleucine, methionine, aspartic acid, glutamic acid, lysine, arginine, glycine, serine, threonine, cysteine, asparagine and glutamine; optionally: alanine or asparagine;

[0188] - any one of the following amino acids: lysine, arginine and histidine; or

[0189] - basic amino acids, such as lysine (K) or arginine (R).

[0190] In some embodiments, the VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of: RSSQSLVHSNGNTYLQ and KSSQSLVHSNGNTYLQ.

[0191] In some embodiments, the VL CDR2 comprises or consists of the amino acid sequence shown by KVSNRFS.

[0192] In some embodiments, the VL CDR3 comprises or consists of the amino acid sequence shown by CSQSIHVPY.

[0193] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region comprising a heavy chain variable region comprising VH CDR1, VH CDR2, and VH CDR3.

[0194] In some embodiments, the VH CDR1 comprises or consists of the amino acid sequence shown in DYEMH.

[0195] In some embodiments, the VH CDR2 comprises or consists of the amino acid sequence shown in GIHPGSGGTAYX2QKFX3G (SEQ ID NO: 64),

[0196] The symbol X2 represents:

[0197] - aliphatic amino acids;

[0198] - any one of the following amino acids: alanine, valine, leucine, isoleucine, methionine, aspartic acid, glutamic acid, lysine, arginine, glycine, serine, threonine, cysteine, asparagine and glutamine; or

[0199] - alanine (A) or asparagine (N), and / or

[0200] The symbol X3 represents:

[0201] - aliphatic amino acids;

[0202] - any one of the following amino acids: alanine, valine, leucine, isoleucine, methionine, aspartic acid, glutamic acid, lysine, arginine, glycine, serine, threonine, cysteine, asparagine and glutamine; or

[0203] -Lysine (K) or glutamine (Q).

[0204] In some embodiments, the VH CDR3 comprises or consists of the amino acid sequence represented by YYSFAYWGQG.

[0205] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region and a heavy chain variable region,

[0206] The light chain variable region comprises:

[0207] VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of RSSQSLVHSNGNTYLQ and KSSQSLVHSNGNTYLQ,

[0208] VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of KVSNRFS, and

[0209] VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY;

[0210] and / or,

[0211] The heavy chain variable region comprises:

[0212] VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH,

[0213] VH CDR2 comprising or consisting of an amino acid sequence selected from the group consisting of GIHPGSGGTAYNQKFKG, GIHPGSGGTAYNQKFQG, and GIHPGSGGTAYAQKFQG, and

[0214] VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

[0215] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region and a heavy chain variable region,

[0216] The light chain variable region comprises:

[0217] VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of: RSSQSLVHSNGNTYLQ,

[0218] VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of KVSNRFS, and

[0219] VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY;

[0220] and

[0221] The heavy chain variable region comprises:

[0222] VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH,

[0223] VH CDR2, which comprises or consists of an amino acid sequence selected from the group consisting of: GIHPGSGGTAYNQKFKG, and

[0224] VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

[0225] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region and a heavy chain variable region,

[0226] The light chain variable region comprises:

[0227] VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of: KSSQSLVHSNGNTYLQ,

[0228] VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of KVSNRFS, and

[0229] VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY;

[0230] and

[0231] The heavy chain variable region comprises:

[0232] VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH,

[0233] VH CDR2 comprises or consists of an amino acid sequence selected from the group consisting of: GIHPGSGGTAYAQKFQG, and

[0234] VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

[0235] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region and a heavy chain variable region,

[0236] The light chain variable region comprises:

[0237] VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of: RSSQSLVHSNGNTYLQ,

[0238] VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of KVSNRFS, and

[0239] VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY;

[0240] and

[0241] The heavy chain variable region comprises:

[0242] VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH,

[0243] VH CDR2 comprises or consists of an amino acid sequence selected from the group consisting of: GIHPGSGGTAYNQKFQG, and

[0244] VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

[0245] In some embodiments, the present invention provides a monoclonal antibody or antigen-binding fragment thereof comprising the following light chain variable region and heavy chain variable region, wherein the VL CDR1, VL CDR2 and VL CDR3 and the VH CDR1, VH CDR2 and VH CDR3 in the light chain variable region and heavy chain variable region comprise or consist of the amino acid sequences shown in Table 1 below:

[0246] Table 1

[0247] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 11. In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 11, and the amino acid sequence has the same or similar biological function and / or activity as SEQ ID NO: 11.

[0248] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 31. In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region comprises an amino acid sequence having at least 80%, at least 81%, at least 82%, at least 83%, at least 84%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 31, and the amino acid sequence has the same or similar biological function and / or activity as SEQ ID NO: 31.

[0249] In some embodiments, the monoclonal antibodies or antigen-binding fragments thereof of the present invention can bind to GPC3 protein in vitro with an EC50 of less than 1 nM. In some embodiments, the monoclonal antibodies or antigen-binding fragments thereof of the present invention can bind to GPC3 protein on the surface of HepG2 cells with an EC50 of less than 5 nM. In some embodiments, the monoclonal antibodies or antigen-binding fragments thereof of the present invention can effectively kill tumor cells (e.g., HepG2) after being conjugated to a cytotoxin (e.g., vcMMAE).

[0250] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 11, 15, 19, 23 and 27.

[0251] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the heavy chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 31, 35, 39, 43 and 47.

[0252] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 11, 15, 19, 23 and 27; and wherein the heavy chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 31, 35, 39, 43 and 47.

[0253] In some embodiments, the present invention provides a monoclonal antibody or antigen-binding fragment thereof comprising the light chain variable region and heavy chain variable region as shown in the amino acid sequence of Table 2 below, or consisting of the amino acid sequence thereof:

[0254] Table 2

[0255] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention further comprises a heavy chain constant region. In some embodiments, the heavy chain constant region comprises or consists of the following amino acid sequence: SEQ ID NO: 51.

[0256] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention further comprises a light chain constant region. In some embodiments, the light chain constant region comprises or consists of the following amino acid sequence: SEQ ID NO: 52.

[0257] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention further comprises a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region comprises or consists of the following amino acid sequence: SEQ ID NO: 51; and the light chain constant region comprises or consists of the following amino acid sequence: SEQ ID NO: 52.

[0258] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region and a heavy chain constant region, wherein the heavy chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 31, 35, 39, 43 and 47, and the heavy chain constant region comprises or consists of the following amino acid sequence: SEQ ID NO: 51.

[0259] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain and a light chain, the light chain comprises a light chain variable region and a light chain constant region, the light chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 11, 15, 19, 23 and 27, and the light chain constant region comprises or consists of the following amino acid sequence: SEQ ID NO: 52.

[0260] In some embodiments, the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region and a heavy chain constant region, wherein the heavy chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 31, 35, 39, 43 and 47, and the heavy chain constant region comprises or consists of the amino acid sequence: SEQ ID NO: 51; and the light chain comprises a light chain variable region and a light chain constant region, wherein the light chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 11, 15, 19, 23 and 27, and the light chain constant region comprises or consists of the amino acid sequence: SEQ ID NO: 52.

[0261] In some embodiments, the present invention provides a monoclonal antibody or antigen-binding fragment thereof comprising the light chain variable region and light chain constant region and the heavy chain variable region and heavy chain constant region as shown in the amino acid sequence of Table 3 below, or consisting of the amino acid sequence thereof:

[0262] Table 3

[0263] In some embodiments, the present invention provides a monoclonal antibody or antigen-binding fragment thereof comprising a light chain and a heavy chain as shown in the amino acid sequence of Table 4 below, or consisting of the amino acid sequence:

[0264] Table 4

[0265] (III) Nucleic Acids, Vectors, Host Cells, Hybridomas, and Antibody Production Methods

[0266] On the one hand, the present invention provides isolated nucleic acid molecules, which encode the aforementioned antibody of the present invention or its Fab.In some embodiments, each CDR in the heavy chain and / or light chain variable region, heavy chain and / or light chain variable region of the aforementioned antibody of the present invention of nucleic acid molecule encoding of the present invention, and heavy chain and / or light chain constant region.In some embodiments, the nucleotide sequence of the nucleic acid molecules is codon optimized for the host cell for expression.In some embodiments, nucleic acid molecules of the present invention are operably connected with expression control sequence.

[0267] In some embodiments, the nucleic acid molecule of the present invention comprises a nucleotide sequence selected from any one of the following or consists of a nucleotide sequence: SEQ ID NOs: 1, 2, 3, 4 and 5, and / or the nucleic acid molecule comprises a nucleotide sequence selected from any one of the following or consists of a nucleotide sequence: SEQ ID NOs: 6, 7, 8, 9 and 10. In some embodiments, the nucleic acid molecule of the present invention comprises or consists of a nucleotide sequence selected from any one of the following combinations: SEQ ID NO: 1 and SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 2, SEQ ID NO: 8 and SEQ ID NO: 2, SEQ ID NO: 9 and SEQ ID NO: 2, SEQ ID NO: 10 and SEQ ID NO: 2, SEQ ID NO: 8 and SEQ ID NO: 3, SEQ ID NO: 9 and SEQ ID NO: 3, SEQ ID NO: 10 and SEQ ID NO: 3, SEQ ID NO: 7 and SEQ ID NO: 4, SEQ ID NO: 8 and SEQ ID NO: 4, SEQ ID NO: 9 and SEQ ID NO: 4, SEQ ID NO: 10 and SEQ ID NO: 4, SEQ ID NO: 8 and SEQ ID NO: 5, SEQ ID NO: 9 and SEQ ID NO: 5, and SEQ ID NO: 10 and SEQ ID NO: 5.

[0268] The present invention also provides an expression vector comprising at least one of the aforementioned nucleic acid molecules of the present invention.

[0269] The present invention also provides a host cell transformed with at least one of the aforementioned nucleic acid molecules or expression vectors of the present invention.

[0270] The present invention also provides hybridoma cells that express at least one of the aforementioned monoclonal antibodies of the present invention or antigen-binding fragments thereof.

[0271] The present invention also provides a method for producing the antibody or antigen-binding fragment thereof of the present invention, comprising:

[0272] (i) culturing the host cell of the present invention under conditions suitable for expression of the nucleic acid molecule or expression vector, and

[0273] (ii) isolating and purifying the antibody or antigen-binding fragment thereof expressed by the host cell.

[0274] In some embodiments, the nucleotide sequence of the nucleic acid molecule is codon-optimized for the host cell for expression. In some embodiments, the nucleic acid molecule is operably linked to an expression control sequence. In some embodiments, the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, and 5, and / or the nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 6, 7, 8, 9, and 10. In some embodiments, the nucleic acid molecule comprises or consists of a nucleotide sequence selected from any one of the following combinations: SEQ ID NO: 1 and SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 2, SEQ ID NO: 8 and SEQ ID NO: 2, SEQ ID NO: 9 and SEQ ID NO: 2, SEQ ID NO: 10 and SEQ ID NO: 2, SEQ ID NO: 8 and SEQ ID NO: 3, SEQ ID NO: 9 and SEQ ID NO: 3, SEQ ID NO: 10 and SEQ ID NO: 3, SEQ ID NO: 7 and SEQ ID NO: 4, SEQ ID NO: 8 and SEQ ID NO: 4, SEQ ID NO: 9 and SEQ ID NO: 4, SEQ ID NO: 10 and SEQ ID NO: 4, SEQ ID NO: 8 and SEQ ID NO: 5, SEQ ID NO: 9 and SEQ ID NO: 5, and SEQ ID NO: 10 and SEQ ID NO: 5.

[0275] The present invention also provides a method for producing the antibody or antigen-binding fragment thereof of the present invention, comprising:

[0276] (i) preparing hybridoma cells capable of expressing a monoclonal antibody or antigen-binding fragment thereof of the present invention, and

[0277] (ii) isolating and purifying the antibody or antigen-binding fragment thereof expressed by the hybridoma cell.

[0278] (IV) Antibody-drug conjugates

[0279] In one aspect, the present invention provides an antibody-drug conjugate (ADC) prepared from the antibody or antigen-binding fragment thereof of the present invention.

[0280] Specifically, the present invention provides an antibody drug conjugate, Ab-LD, of the following formula, wherein:

[0281] The symbol "Ab" represents at least one of the aforementioned monoclonal antibodies of the present invention or an antigen-binding fragment thereof;

[0282] The symbol "L" represents a linker that connects the antibody portion and the partner molecule; and

[0283] The symbol "D" represents a partner molecule.

[0284] As used herein, ADCs are prepared by linking a partner molecule to an antibody or antigen-binding fragment thereof via a linker. In the ADCs of the present invention, the antibody performs a targeting function: by binding to the target tissue or cell where its antigen is found, the antibody directs the conjugate to that target tissue or cell. There, the linker is, for example, cleaved, releasing the partner molecule to perform its desired biological function.

[0285] The partner molecule can be a drug payload or a labeling molecule. The drug payload can be a therapeutic agent, for example, a cytotoxic agent, a chemotherapeutic agent, a cytostatic agent, an immunomodulatory agent, etc. In some embodiments, the therapeutic agent is a cytotoxic agent, i.e., a cytotoxin. As used herein, the terms "cytotoxic agent" and "cytotoxin" are used interchangeably.

[0286] The labeling molecule can be any label that produces a detectable signal, such as a radioactive label, a fluorescent label, or an enzyme that catalyzes a detectable modification of a substrate.

[0287] As used herein, the terms "drug," "payload," and "drug payload" are used interchangeably. As used herein, an antibody-drug conjugate (ADC) encompasses a conjugate formed by linking an antibody of the invention or an antigen-binding fragment thereof to a drug payload, as well as a conjugate formed by linking an antibody of the invention or an antigen-binding fragment thereof to a labeling molecule.

[0288] The ratio of partner molecules attached to the antibody can vary depending on factors such as the amount of partner molecules used during the conjugation reaction and the experimental conditions. The ratio of partner molecules to antibody can be 1 to 6, 1 to 5, 1 to 4, 1 to 3, 1 to 2, or 1 to 1.5.

[0289] Therefore, the present invention also provides an antibody drug conjugate of the following formula, Ab-(LD)p, wherein:

[0290] The symbol "Ab" represents at least one of the aforementioned monoclonal antibodies of the present invention or an antigen-binding fragment thereof;

[0291] The symbol “L” represents a linker connecting the antibody portion and the partner molecule;

[0292] The symbol "D" represents a partner molecule; and

[0293] The symbol "p" represents the number of linker / partner molecules (preferably drug cargo) conjugated to the aforementioned portion of the monoclonal antibody or antigen-binding fragment thereof of the present invention.

[0294] In some embodiments, p is selected from the following values: 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4. 3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, and 8.0.

[0295] In some embodiments, the linker of the present invention is selected from the group consisting of vc, mc-GGFG, AcLysvc, mc, MalPeg6, m(H20)c, and m(H20)cvc; and / or the linker is cleavable. In some embodiments, the linker of the present invention is vc.

[0296] In some embodiments, the partner molecule of the present invention is a drug payload, and the drug payload is a therapeutic molecule; optionally, the drug payload is selected from one of the following: a cytotoxic agent, a cytostatic agent, an immunomodulatory agent, and a chemotherapeutic agent; optionally, the drug payload is selected from one of the following: MMAE, MMAF, DM1, DM4, Dxd, SN-38, Topotecan and its derivatives, Exatecan and its derivatives, Belotecan and its derivatives, Camptothecin, Calichemicin, and PBD.

[0297] In some embodiments, the drug cargo is MMAE. "MMAE" refers to monomethyl auristatin E, as shown in the figure below, where the wavy line indicates the covalent attachment to the linker (L) of the antibody drug conjugate:

[0298] In some embodiments, the drug cargo is MMAF. MMAF refers to monomethyl auristatin F, where the wavy line indicates covalent attachment to the linker (L) of the antibody drug conjugate (US2005 / 0238649):

[0299] In some embodiments, the linker-partner molecule is vcMMAE. vcMMAE drug linker moieties and conjugation methods are disclosed in WO2004010957, US7659241, US7829531, US7851437, and US 11 / 833,028 (Seattle Genetics, Inc.), which are incorporated herein by reference. Using methods similar to those disclosed in the above-mentioned literature, the vcMMAE drug linker moiety is conjugated to the antibodies of the present invention.

[0300] For further discussion of types of cytotoxins, linkers and methods for conjugating therapeutic agents to antibodies, see Saito, G. et al. (2003) Adv. Drug Deliv. Rev. 55: 199-215; Trail, PA et al. (2003) Cancer. Immunol. Immunother. 52: 328-337; Payne, G. (2003) Cancer Cell 3: 207-212; Allen, TM (2002) Nat. Rev. Cancer 2: 750-763; Pastan, I. and Kreitman, RJ (2002) Curr. Opin. Investig. Drugs 3: 1089-1091; Senter, PD and Springer, CJ (2001) Adv. Drug Deliv. Rev. 53: 247-264, which are incorporated herein by reference.

[0301] In some embodiments, the drug payload may further be a radioisotope, thereby producing a cytotoxic radiopharmaceutical (also known as an antibody radioisotope conjugate). Examples of radioisotopes that are cytotoxic to tumor cells include, but are not limited to, iodine-131, indium-111, yttrium-90, and lutetium-177. Methods for preparing antibody radioisotope conjugates are known in the art.

[0302] In some embodiments, the partner molecule of the present invention is a labeling molecule; optionally, the labeling molecule is selected from the group consisting of a radioactive label, a fluorescent label, and a detectably modified enzyme. In some embodiments, the radioactive label is a radioisotope, such as iodine-131, indium-111, yttrium-90, and lutetium-177.

[0303] Experiments have shown that GPC3 protein can be used as an effective target for antibody-drug conjugates. The antibody-drug conjugates obtained by coupling antibodies with small molecule toxins can produce excellent killing effects on tumors expressing GPC3 protein.

[0304] (V) Pharmaceutical compositions, therapeutic uses and methods

[0305] The present invention provides pharmaceutical compositions comprising a therapeutically effective amount of at least one monoclonal antibody or antigen-binding fragment thereof of the present invention, or at least one antibody-drug conjugate of the present invention, as well as therapeutic uses and methods of treatment thereof. In the antibody-drug conjugates of the present invention, the antibody of the present invention is conjugated to a drug cargo.

[0306] In one aspect, the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of at least one monoclonal antibody or antigen-binding fragment thereof of the present invention or at least one antibody-drug conjugate of the present invention. In some embodiments, the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier.

[0307] A "therapeutically effective amount" of at least one of the aforementioned monoclonal antibodies or antigen-binding fragment portions thereof, or at least one of the aforementioned antibody-drug conjugates of the present invention, preferably results in a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease-free periods, or prevents impairment or disability caused by the affliction of the disease. For example, for the treatment of tumors, a "therapeutically effective amount" of at least one of the aforementioned monoclonal antibodies or antigen-binding fragment portions thereof, or at least one of the aforementioned antibody-drug conjugates of the present invention, preferably inhibits cell growth or tumor growth by at least about 10%, preferably at least about 20%, more preferably at least about 30%, more preferably at least about 40%, more preferably at least about 50%, more preferably at least about 60%, more preferably at least about 70%, and more preferably at least about 80%, relative to an untreated subject. The ability to inhibit tumor growth can be evaluated in animal model systems that are predictive of efficacy against human tumors. Alternatively, it can be evaluated by examining the ability to inhibit cell growth, which inhibition can be measured in vitro using assays known to those skilled in the art. An effective amount of an antibody or antigen-binding fragment thereof of the present invention is capable of reducing tumor size or otherwise alleviating symptoms in a subject, such as preventing and / or treating metastasis or recurrence. Such an amount can be determined by those skilled in the art based on factors such as the size of the subject, the severity of the subject's symptoms, and the specific composition or route of administration selected.

[0308] In another aspect, the present invention provides the use of at least one monoclonal antibody or antigen-binding fragment thereof of the present invention or at least one antibody-drug conjugate of the present invention in preparing a pharmaceutical composition. In some embodiments, the pharmaceutical composition is used to treat a malignant tumor, prevent and / or treat metastasis or recurrence of a malignant tumor in a patient.

[0309] In another aspect, the present invention provides a pharmaceutical composition comprising at least one monoclonal antibody or antigen-binding fragment thereof of the present invention or at least one antibody-drug conjugate of the present invention, for use in a method for treating a malignant tumor, preventing and / or treating metastasis or recurrence of a malignant tumor in a patient.

[0310] In another aspect, the present invention provides a method for treating a malignant tumor, preventing and / or treating metastasis or recurrence of a malignant tumor in a patient, comprising administering to the patient an effective amount of at least one of the aforementioned monoclonal antibodies or antigen-binding fragments thereof of the present invention, at least one of the aforementioned antibody-drug conjugates of the present invention, and / or at least one of the aforementioned pharmaceutical compositions of the present invention.

[0311] In some embodiments, the malignant tumor is a tumor that expresses the GPC3 protein. In some embodiments, the malignant tumor is selected from breast cancer, colorectal cancer, pancreatic cancer, prostate cancer, liver cancer, lung cancer (small cell lung cancer), and gastric cancer. In some embodiments, the malignant tumor is liver cancer or lung cancer (small cell lung cancer).

[0312] (VI) Diagnostic / prognostic compositions, diagnostic / prognostic uses, and methods

[0313] As described in this article, GPC3 is a tumor-associated antigen that is specifically overexpressed in tumor cells, especially in patients with cancers such as liver cancer and small cell lung cancer, and is expressed on the surface of tumor cells.

[0314] The present invention provides diagnostic / prognostic compositions comprising at least one monoclonal antibody or antigen-binding fragment thereof of the present invention, or at least one antibody-drug conjugate of the present invention, diagnostic / prognostic uses of such compositions, and diagnostic / prognostic methods. In the diagnostic / prognostic drug conjugates of the present invention, the antibody of the present invention is conjugated to a marker molecule. For purposes of diagnostic / prognostic compositions, diagnostic / prognostic uses, and diagnostic / prognostic methods, the antibody-drug conjugate of the present invention refers to a conjugate formed by linking an antibody of the present invention or its antigen-binding fragment to a marker molecule.

[0315] In one aspect, the present invention provides the use of at least one of the aforementioned monoclonal antibodies or antigen-binding fragments thereof of the present invention, or at least one of the aforementioned antibody-drug conjugates of the present invention, in the preparation of a diagnostic / prognostic composition. In some embodiments, the diagnostic composition is used to detect the presence of a malignant tumor in a patient. In some embodiments, the prognostic composition is used to predict the recurrence or progression of a malignant tumor in a patient.

[0316] In another aspect, the present invention provides a method for detecting / diagnosing the presence of a malignant tumor in a patient, comprising administering to the patient an effective amount of at least one of the aforementioned monoclonal antibodies or antigen-binding fragments thereof of the present invention, at least one of the aforementioned antibody-drug conjugates of the present invention, and / or at least one of the aforementioned diagnostic / prognostic compositions of the present invention.

[0317] In some embodiments, the present invention provides a method for detecting / diagnosing the presence of a malignant tumor in a patient, comprising:

[0318] a) contacting a biological sample obtained from the patient with at least one of the aforementioned monoclonal antibodies or antigen-binding fragments thereof of the present invention, at least one of the aforementioned antibody-drug conjugates of the present invention, and / or at least one of the aforementioned diagnostic / prognostic compositions of the present invention;

[0319] b) detecting binding of at least one of the aforementioned monoclonal antibodies of the present invention or antigen-binding fragments thereof, at least one of the aforementioned antibody drug conjugates of the present invention, and / or at least one of the aforementioned diagnostic / prognostic compositions of the present invention to a target antigen in the biological sample, wherein detection of binding of the antibody to the target antigen indicates the presence of a malignant tumor in the patient.

[0320] In another aspect, the present invention provides a method for prognosing recurrence or progression of a malignant tumor in a patient, comprising administering to the patient an effective amount of at least one of the aforementioned monoclonal antibodies or antigen-binding fragments thereof of the present invention, at least one of the aforementioned antibody-drug conjugates of the present invention, and / or at least one of the aforementioned diagnostic / prognostic compositions of the present invention.

[0321] In some embodiments, the present invention provides a method for prognosing recurrence or progression of a malignant tumor in a patient, the method comprising:

[0322] (a) isolating a biological sample comprising tumor cells from the patient;

[0323] (b) contacting the biological sample comprising tumor cells with at least one of the aforementioned monoclonal antibodies or antigen-binding fragments thereof of the present invention, at least one of the aforementioned antibody-drug conjugates of the present invention, and / or at least one of the aforementioned diagnostic / prognostic compositions of the present invention; and

[0324] (c) identifying that the binding of the antibody to the tumor cell represents the presence of the tumor cell,

[0325] The recurrence or progression of the malignancy in said patient is thereby prognosed.

[0326] In some embodiments, the progression of the malignancy comprises metastasis of the malignancy in the patient.

[0327] In some embodiments, the presence of tumor cells identified to which at least one of the aforementioned monoclonal antibodies or antigen-binding fragments thereof of the invention, at least one of the aforementioned antibody drug conjugates of the invention, and / or at least one of the aforementioned diagnostic / prognostic compositions of the invention is bound indicates a high risk of recurrence or progression of the malignancy in the patient.

[0328] In some embodiments, the partner molecule of the present invention is a labeling molecule; optionally, the labeling molecule is selected from the following: a radioactive label (eg, an isotope), a fluorescent label (eg, a fluorescent dye), a chemical substance, and a detectably modified enzyme and tag.

[0329] In some embodiments, the biological sample is selected from one of the following: a blood sample, a tissue sample, and a lymph sample.

[0330] Methods for detecting antibody-antigen binding are known in the art, such as ELISA and the like.

[0331] (VII) Test kit

[0332] Also within the scope of the present invention are kits for use in the methods of the present invention, comprising at least one aforementioned monoclonal antibody or antigen-binding fragment thereof of the present invention, at least one aforementioned antibody-drug conjugate of the present invention, at least one aforementioned pharmaceutical composition of the present invention, or one aforementioned diagnostic / prognostic composition of the present invention, and instructions for use.

[0333] In some embodiments, the kit may further include at least one additional detection reagent for detecting the presence of at least one of the aforementioned monoclonal antibodies or antigen-binding fragments thereof of the present invention, at least one of the aforementioned antibody-drug conjugates of the present invention, at least one of the aforementioned pharmaceutical compositions of the present invention, or one of the aforementioned diagnostic / prognostic compositions of the present invention. The kit generally includes a label indicating the intended use and / or method of use of the contents of the kit. The term label includes any written or recorded material provided on or with the kit or otherwise provided with the kit.

[0334] Example

[0335] A further understanding of the present invention may be obtained by reference to some of the specific embodiments provided herein, which are intended to illustrate the present invention only and are not intended to limit the scope of the present invention in any way. Obviously, various modifications and variations may be made to the present invention without departing from the spirit of the present invention, and therefore, such modifications and variations are also within the scope of the present application.

[0336] Example 1 - Preparation of GPC3 Antibody

[0337] 1. Vector Construction

[0338] The design, vector construction, expression, purification, and identification of the GPC3 antibody sequence of the present invention were all entrusted to Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. The construction process primarily involved constructing the GPC3 antibody sequence onto the pcDNA3.4 vector, followed by PCR, enzyme digestion, ligation, transformation, identification, sequencing, alignment, and extraction to obtain plasmids. The vectors containing the GPC3 antibody sequence of the present invention are as follows (5 light chain plasmids: 5 kappa class; 5 heavy chain plasmids: 5 IgG1 class):

[0339] Light chain coding sequence (the shaded area corresponds to the constant region sequence):

[0340] Chimeric murine antibody light chain coding sequence: FS001-mVL-LC (kappa) (SEQ ID NO: 1), which is used to express the murine light chain variable region + human light chain constant region

[0341] Humanized antibody light chain coding sequence: FS001-VL1-LC (kappa) (SEQ ID NO: 2), which is used to express humanized light chain variable region + human light chain constant region

[0342] Humanized antibody light chain coding sequence: FS001-VL2-LC (kappa) (SEQ ID NO: 3), which is used to express humanized light chain variable region + human light chain constant region

[0343] Humanized antibody light chain coding sequence: FS001-VL3-LC (kappa) (SEQ ID NO: 4), which is used to express humanized light chain variable region + human light chain constant region

[0344] Humanized antibody light chain coding sequence: FS001-VL4-LC (kappa) (SEQ ID NO: 5), which is used to express humanized light chain variable region + human light chain constant region

[0345] Heavy chain coding sequence (the shaded area corresponds to the constant region sequence):

[0346] Chimeric murine antibody heavy chain coding sequence: FS001-mVH-HC (IgG1) (SEQ ID NO: 6), which is used to express the murine heavy chain variable region + human heavy chain constant region

[0347] Humanized antibody heavy chain coding sequence: FS001-VH1-HC (IgG1) (SEQ ID NO: 7), which is used to express humanized heavy chain variable region + human heavy chain constant region

[0348] Humanized antibody heavy chain coding sequence: FS001-VH2-HC (IgG1) (SEQ ID NO: 8), which is used to express humanized heavy chain variable region + human heavy chain constant region

[0349] Humanized antibody heavy chain coding sequence: FS001-VH3-HC (IgG1) (SEQ ID NO: 9), which is used to express humanized heavy chain variable region + human heavy chain constant region

[0350] Humanized antibody heavy chain coding sequence: FS001-VH4-HC (IgG1) (SEQ ID NO: 10), which is used to express humanized heavy chain variable region + human heavy chain constant region

[0351] The amino acid sequences of the light chain variable region and heavy chain variable region of the antibody expressed by the above vector are as follows:

[0352] Light chain variable region (amino acid sequence):

[0353] (1) Mouse antibody light chain variable region (FS001-mVL: SEQ ID NO: 11)

[0354] The underlined italic parts indicate mVL-CDR1 (SEQ ID NO: 12: RSSQSLVHSNGNTYLQ), mVL-CDR2 (SEQ ID NO: 13: KVSNRFS), and mVL-CDR3 (SEQ ID NO: 14: CSQSIHVPY), respectively.

[0355] (2) Humanized light chain variable region (FS001-VL1: SEQ ID NO: 15)

[0356] The underlined italic parts respectively indicate VL1-CDR1 (SEQ ID NO: 16: RSSQSLVHSNGNTYLQ), VL1-CDR2 (SEQ ID NO: 17: KVSNRFS), and VL1-CDR3 (SEQ ID NO: 18: CSQSIHVPY).

[0357] (3) Humanized light chain variable region (FS001-VL2: SEQ ID NO: 19)

[0358] The underlined italic parts respectively indicate VL2-CDR1 (SEQ ID NO: 20: RSSQSLVHSNGNTYLQ), VL2-CDR2 (SEQ ID NO: 21: KVSNRFS), and VL2-CDR3 (SEQ ID NO: 22: CSQSIHVPY).

[0359] (4) Humanized light chain variable region (FS001-VL3: SEQ ID NO: 23)

[0360] The underlined italic parts respectively indicate VL3-CDR1 (SEQ ID NO: 24: RSSQSLVHSNGNTYLQ), VL3-CDR2 (SEQ ID NO: 25: KVSNRFS), and VL3-CDR3 (SEQ ID NO: 26: CSQSIHVPY).

[0361] (5) Humanized light chain variable region (FS001-VL4: SEQ ID NO: 27)

[0362] The underlined italic parts respectively indicate VL4-CDR1 (SEQ ID NO: 28: KSSQSLVHSNGNTYLQ), VL4-CDR2 (SEQ ID NO: 29: KVSNRFS), and VL4-CDR3 (SEQ ID NO: 30: CSQSIHVPY).

[0363] Heavy chain variable region (amino acid sequence):

[0364] (1) Murine antibody heavy chain variable region (FS001-mVH: SEQ ID NO: 31)

[0365] The underlined italic parts indicate mVH-CDR1 (SEQ ID NO: 32: ), mVH-CDR2 (SEQ ID NO: 33: )、mVH-CDR3 (SEQ ID NO: 34: ).

[0366] (2) Humanized heavy chain variable region (FS001-VH1: SEQ ID NO: 35)

[0367] The underlined italic parts indicate VH1-CDR1 (SEQ ID NO: 36: )、VH1-CDR2(SEQ ID NO:37: ), VH1-CDR3 (SEQ ID NO: 38: ).

[0368] (3) Humanized heavy chain variable region (FS001-VH2: SEQ ID NO: 39)

[0369] The underlined italic parts indicate VH2-CDR1 (SEQ ID NO: 40: ), VH2-CDR2 (SEQ ID NO: 41: )、VH2-CDR3 (SEQ ID NO: 42: ).

[0370] (4) Humanized heavy chain variable region (FS001-VH3: SEQ ID NO: 43)

[0371] The underlined italic parts indicate VH3-CDR1 (SEQ ID NO: 44: ), VH3-CDR2 (SEQ ID NO: 45: ), VH3-CDR3 (SEQ ID NO: 46: ).

[0372] (5) Humanized heavy chain variable region (FS001-VH4: SEQ ID NO: 47)

[0373] The underlined italic parts indicate VH4-CDR1 (SEQ ID NO: 48: ), VH4-CDR2 (SEQ ID NO: 49: ), VH4-CDR3 (SEQ ID NO: 50: ).

[0374] The above heavy chain variable region is directly linked to the amino acid sequence of the following human heavy chain constant region, and the above light chain variable region is directly linked to the amino acid sequence of the following human light chain constant region:

[0375] Human light chain constant region (SEQ ID NO: 51):

[0376] Human heavy chain constant region (SEQ ID NO: 52):

[0377] The amino acid sequences of the full-length heavy chain and full-length light chain of the antibody prepared in this example are as follows:

[0378] Light chain (amino acid sequence) (the shaded area corresponds to the constant region sequence):

[0379] (1) Mouse antibody light chain variable region + human light chain constant region (FS001-mVL-LC (kappa): SEQ ID NO: 53)

[0380] (2) Humanized light chain variable region + human light chain constant region (FS001-VL1-LC (kappa): SEQ ID NO: 54)

[0381] (3) Humanized light chain variable region + human light chain constant region (FS001-VL2-LC (kappa): SEQ ID NO: 55)

[0382] (4) Humanized light chain variable region + human light chain constant region (FS001-VL3-LC (kappa): SEQ ID NO: 56)

[0383] (5) Humanized light chain variable region + human light chain constant region (FS001-VL4-LC (kappa): SEQ ID NO: 57)

[0384] Heavy chain (amino acid sequence) (the shaded area corresponds to the constant region sequence):

[0385] (1) Murine antibody heavy chain variable region + human heavy chain constant region (FS001-mVH-HC (IgG1): SEQ ID NO: 58)

[0386] (2) Humanized heavy chain variable region + human heavy chain constant region (FS001-VH1-HC (IgG1): SEQ ID NO: 59)

[0387] (3) Humanized heavy chain variable region + human heavy chain constant region (FS001-VH2-HC (IgG1): SEQ ID NO: 60)

[0388] (4) Humanized heavy chain variable region + human heavy chain constant region (FS001-VH3-HC (IgG1): SEQ ID NO: 61)

[0389] (5) Humanized heavy chain variable region + human heavy chain constant region (FS001-VH4-HC (IgG1): SEQ ID NO: 62)

[0390] The antibodies constructed in this example are as follows:

[0391] Table 1

[0392] 2. Antibody expression and purification, and SDS-PAGE identification

[0393] The plasmid was expressed in CHO cells for 7 days using the ExpiCHO-s expression system as required, and the antibody was purified by Protein A affinity chromatography on the 6th day of expression.

[0394] Subsequently, the purity of the resulting antibody was tested by SDS-PAGE. In SDS-PAGE, the purity of the reduced band, or the combined purity of the reduced heavy and light chains, was calculated using ImageJ using the peak area normalization method. The non-reduced band of the reference IPI had a molecular weight of approximately 150 kDa, indicating a purity greater than 90%. The reduced heavy chain had a molecular weight of approximately 55 kDa, and the light chain had a molecular weight of approximately 25 kDa, indicating a purity greater than 90% for both heavy and light chains.

[0395] 3. Antibody affinity kinetics testing

[0396] Open the GATOR instrument and related software and select the Kinetics experimental mode. The analysis procedure is as follows:

[0397] Table 2

[0398] The global fitting model affinity kinetics test results obtained are as follows:

[0399] Table 3

[0400] The experimental results show that the correlation coefficient R of all antibodies in the Global fitting mode 2They are all greater than 0.95, which meets the system adaptability requirements and the results are reliable.

[0401] Example 2 - Determination of the affinity of GPC3 antibodies to GPC3 at the protein level by ELISA

[0402] The affinity of the aforementioned GPC3 antibody to GPC3 at the protein level was determined by the following method, including: coating an ELISA plate with GPC3-His (2 μg / mL, 1*PBS), 30 μL per well, and incubating overnight at 4°C; washing the plate three times with PBST and blocking the plate with 5% PBS-milk at room temperature for 2 hours; washing the plate and adding the diluted antibody (diluted in 1% milk) to the ELISA plate, 30 μL per well, and incubating at room temperature for 60 minutes; washing the plate three times with PBST, and then adding 1:4000 anti-human Fc-HRP (abcam; ab97225; diluted in 1% milk) and incubating at room temperature for 60 minutes; washing the plate three times with PBST; adding tetramethylbenzidine, 30 μL per well; stopping the reaction with 2M stop solution, and reading the OD450 reading.

[0403] The results of affinity determination are shown in Table 4. As shown in the table, all 15 antibodies were able to bind to GPC3 protein well, with EC50 values ​​of less than 1 nM.

[0404] Table 4

[0405] Example 3 - Determination of the affinity of GPC3 antibodies to GPC3 at the cellular level by flow cytometry

[0406] HepG2 human hepatoma cells were plated into a 96-well plate at 50,000 cells per well. The cells were then washed twice with PBS by pipetting, and the PBS was discarded. The primary antibody to be tested, GPC3, was prepared at a working concentration of 30 nM in 1% FBS / PBS and diluted three-fold to a total of five specific concentrations. The prepared antibody dilutions were added to the corresponding 96-well plates and incubated at 4°C for 30 minutes. The cells were then washed twice with 1% FBS / PBS by pipetting, and the PBS was discarded by centrifugation. The supernatant was then discarded. A secondary goat anti-human IgG (H+L) antibody, designed to eliminate cross-recognition from other species, was prepared at a 1:300 dilution in 10% FBS / PBS. The cells were added to the 96-well plates and incubated at 4°C for 30 minutes. Flow cytometry was used to collect and analyze the cells. The EC50 and median fluorescence intensity (MFI) at the highest concentration were used to comprehensively evaluate the antibody's affinity for the GPC3 target. Condrituzumab (purchased from Bio-Bio) was used as a positive control antibody for binding to GPC3.

[0407] The results of EC50 determination are shown in Figure 1. As shown in Figure 1, all 15 GPC3 antibodies were able to effectively bind to HepG2 cells. Among these 15 antibodies, 11 had an EC50 of less than 5 nM. Specifically, FS001-huVH1+huVL1 had a 1.43-fold greater ability to bind to HepG2 cells than codrituzumab, 1.66-fold greater for FS001-huVH3+huVL1, 1.45-fold greater for FS001-huVH2+huVL2, 1.82-fold greater for FS001-huVH3+huVL2, 2.76-fold greater for FS001-huVH4+huVL2, 1.89-fold greater for FS001-huVH4+huVL3, and 1.45-fold greater for FS001-huVH4+huVL4. The binding abilities of the other four antibodies, including FS001-VH4-VL1, were slightly weaker than those of the positive control antibody, but they could also bind to GPC3 well.

[0408] The results of MFI measurement are shown in Figure 2. As shown in Figure 2, all 15 GPC3 antibodies can bind to HepG2 cells.

[0409] Example 4 - Preparation of Antibody-Drug Conjugates (ADCs)

[0410] Antibody-drug conjugates were prepared using the following method

[0411] Materials and methods:

[0412] Coupling buffer: 25mM Na2B4O7, 25mM NaCl, 1mM DPTA, pH 7.4

[0413] Dialysis buffer: 1× PBS, pH 7.4

[0414] Antibody reduction concentration: 5mg / mL

[0415] Tris(2-chloroethyl) phosphate (TCEP): 5 mM, binding buffer

[0416] TCEP:antibody=2.3:1

[0417] Payload: 10 mM linker-payload, dimethyl sulfoxide (DMSO)

[0418] DMSO in final reaction: 10%

[0419] Payload:antibody=10:1

[0420] Reduction temperature and time: 25°C and 2 hours

[0421] Coupling temperature and time: 25 °C and 4 hours

[0422] Coupling steps:

[0423] Thaw and dialyze the antibody using coupling buffer at 4°C for >4 hours;

[0424] If necessary, concentrate the antibody solution to 2-5 mg / ml;

[0425] Add TCEP working solution to reduce the antibody and incubate in a 25°C water bath;

[0426] Prepare linker-load solution in DMSO (10 mM);

[0427] The volume of the effective linker-load solution for each conjugation was calculated based on the molar concentration;

[0428] Mix the antibody with the linker-load at the desired molar ratio and incubate in a 25°C water bath;

[0429] Dialyze the conjugate against ADC storage buffer at 4°C for greater than 4 hours, changing the buffer at least every 4 hours; and

[0430] ADCs were extracted and filtered using a 0.22 μm filter, and samples were submitted for UV, SEC-HPLC, and HIC-HPLC analysis.

[0431] By the above method, using vc-MMAE (mc-vc-PAB-MMAE, C68H105N11O15, provided by Ruizhi Chemical) as a linker-payload, antibody-drug conjugates of FS001-VH4-VL1, FS001-VH3-VL2, FS001-VH4-VL2 and FS001-VH4-VL3 were prepared in this example.

[0432] Table 5

[0433] By the above method, Dxd (MC-GGFG-DXD, HY13MY2801, provided by Wise Chem) was also used as a linker-payload to prepare antibody-drug conjugates of FS001-VH3-VL2 and FS001-VH4-VL3 in this example.

[0434] Table 6

[0435] Example 5 - Biological activity of antibody-drug conjugates (ADCs) using the toxin MMAE on cancer cell killing

[0436] This example tests the biological activity of the antibody of the present invention in killing cancer cells after being conjugated to a toxin to form an ADC.

[0437] ATCC-derived human liver cancer cells HepG2, Zhejiang Meisen-derived human liver cancer cells Huh7, and negative control ATCC-derived Chinese hamster ovary cells CHO were plated into 96-well plates, 2500 cells / well. They were placed in a 37°C 5% CO2 incubator for overnight incubation. The next day, half of the culture medium in the cell plate was removed. 2x FS001-VH4-VL1, FS001-VH4-VL1-vc-MMAE, FS001-VH3-VL2-vc-MMAE, FS001-VH4-VL2-vc-MMAE, FS001-VH4-VL3-vc-MMAE, Codrituzumab-vc-MMAE (GPC3 positive control ADC, provided by Ruizhi Chemical), hIgG1-vcMMAE (negative control ADC, provided by Ruizhi Chemical) were prepared with complete culture medium. Serial dilutions of FS001-VH4-VL1, FS001-VH4-VL1-vc-MMAE, FS001-VH3-VL2-vc-MMAE, FS001-VH4-VL2-vc-MMAE, FS001-VH4-VL3-vc-MMAE, Codrituzumab-vc-MMAE, and hIgG1-vc-MMAE were added to appropriate wells and incubated in a 37°C, 5% CO2 incubator for 5 days. After incubation, 100 μL of Cell-Titer-Glo 2.0 reagent was added to the 96-well plate, mixed on a plate shaker for 2 minutes, and equilibrated at room temperature for 10 minutes. Readings were performed using a microplate reader. IC50 values ​​were used to compare the biological activity of the ADC against various cell lines.

[0438] The results are shown in Table 7. As shown in Table 7, FS001-VH4-VL1-vc-MMAE, FS001-VH3-VL2-vc-MMAE, FS001-VH4-VL2-vc-MMAE, and FS001-VH4-VL3-vc-MMAE all had good killing effects on the human liver cancer cell lines HepG2 and HuH7, but had no killing effect on the negative control CHO cells. The GPC3 antibody (FS001-VH4-VL1) not conjugated with vc-MMAE or the negative control hIgG1-vc-MMAE were unable to effectively kill HepG2 and HuH7 cells.

[0439] These results suggest that GPC3 antibodies alone cannot kill tumor cells in vitro. However, surprisingly, the GPC3 protein can serve as an effective target for antibody-drug conjugates. The antibody-drug conjugates, derived from the present invention by coupling the antibody to a small molecule toxin, exhibit excellent killing effects against tumors expressing the GPC3 protein.

[0440] Table 7

[0441] Example 6 - Biological Activity of Antibody-Drug Conjugates (ADCs) Using Toxin Dxd on Cancer Cell Killing

[0442] This example tests the biological activity of the antibody of the present invention in killing cancer cells after being conjugated to a toxin to form an ADC.

[0443] ATCC-derived human hepatoma cells HepG2, Zhejiang Meisen-derived human hepatoma cells Huh7, Zhejiang Meisen-derived human hepatoma cells JHH7, and negative control ATCC-derived Chinese hamster ovary (CHO) cells were plated into 96-well plates at 2500 cells per well. The plates were incubated overnight at 37°C in a 5% CO2 incubator. The next day, half of the culture medium was removed from the plates. 2x concentrations of FS001-VH3-VL2, FS001-VH4-VL3, FS001-VH3-VL2-Dxd, FS001-VH4-VL3-Dxd, and hIgG1 (negative control antibody, provided by Bio-Bio) were prepared in complete culture medium. Serial dilutions of FS001-VH3-VL2, FS001-VH4-VL3, FS001-VH3-VL2-Dxd, FS001-VH4-VL3-Dxd, and hIgG1 were then added to appropriate wells and incubated in a 37°C, 5% CO2 incubator for 5 days. Following incubation, 100 μL of Cell-Titer-Glo 2.0 reagent was added to the 96-well plate, mixed on a shaker for 2 minutes, and equilibrated at room temperature for 10 minutes. Reading was performed using a microplate reader. Finally, the biological activity of ADC against various cell lines was compared by IC50.

[0444] The results are shown in Table 8.

[0445] Table 8

[0446] As shown in the table, FS001-VH3-VL2-Dxd and FS001-VH4-VL3-Dxd exhibited significant antitumor activity against the human liver cancer cell lines HepG2, HuH7, and JHH7, but showed no antitumor activity against the negative control CHO cells. The IC50 values ​​for these antitumor effects were similar to those of the vc-MMAE ADCs shown in Table 7, demonstrating that the GPC3 antibodies of the present invention can achieve excellent antitumor activity when conjugated to various small molecule toxins. Unconjugated GPC3 antibodies (FS001-VH3-VL2 and FS001-VH4-VL3) or the negative control hIgG1 antibody were ineffective against HepG2, HuH7, and JHH7 cells. These results also suggest that GPC3 antibodies alone cannot be used to kill tumor cells in vitro, but that the GPC3 protein can serve as an effective target for antibody-drug conjugates. The antibody-drug conjugate obtained by coupling different types of small molecule toxins to antibodies in the present invention can produce an excellent killing effect on tumors expressing GPC3 protein.

[0447] Technical solution:

[0448] 1. A monoclonal antibody or an antigen-binding fragment thereof targeting GPC3, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region,

[0449] The light chain variable region comprises:

[0450] VL CDR1 comprises the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 12,

[0451] VL CDR2 comprising the amino acid sequence shown in SEQ ID NO: 13 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 13, and

[0452] VL CDR3 comprising the amino acid sequence of SEQ ID NO: 14, or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted, or added relative to SEQ ID NO: 14;

[0453] and / or,

[0454] The heavy chain variable region comprises:

[0455] VH CDR1 comprising the amino acid sequence of SEQ ID NO: 32 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 32,

[0456] VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 33 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 33, and

[0457] VH CDR3 comprising the amino acid sequence of SEQ ID NO: 34 or comprising an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 34.

[0458] 2. The isolated monoclonal antibody or antigen-binding fragment thereof of technical solution 1, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region,

[0459] The light chain variable region comprises:

[0460] VL CDR1 comprises or consists of the amino acid sequence represented by X1SSQSLVHSNGNTYLQ,

[0461] The symbol X1 represents:

[0462] - aliphatic amino acids;

[0463] - any one of the following amino acids: alanine, valine, leucine, isoleucine, methionine, aspartic acid, glutamic acid, lysine, arginine, glycine, serine, threonine, cysteine, asparagine and glutamine; optionally: alanine or asparagine;

[0464] - any one of the following amino acids: lysine, arginine and histidine; or

[0465] - lysine (K) or arginine (R);

[0466] VL CDR2, which comprises or consists of the amino acid sequence shown in KVSNRFS, and

[0467] VL CDR3, which comprises or consists of the amino acid sequence represented by CSQSIHVPY;

[0468] and / or

[0469] The heavy chain variable region comprises:

[0470] VH CDR1 comprises or consists of the amino acid sequence shown in DYEMH,

[0471] VH CDR2 comprises or consists of the amino acid sequence shown in GIHPGSGGTAYX2QKFX3G,

[0472] The symbol X2 represents:

[0473] - aliphatic amino acids;

[0474] - any one of the following amino acids: alanine, valine, leucine, isoleucine, methionine, aspartic acid, glutamic acid, lysine, arginine, glycine, serine, threonine, cysteine, asparagine and glutamine; or

[0475] - alanine (A) or asparagine (N),

[0476] The symbol X3 represents:

[0477] - aliphatic amino acids;

[0478] - any one of the following amino acids: alanine, valine, leucine, isoleucine, methionine, aspartic acid, glutamic acid, lysine, arginine, glycine, serine, threonine, cysteine, asparagine and glutamine; or

[0479] - lysine (K) or glutamine (Q), and

[0480] VH CDR3 comprises or consists of the amino acid sequence represented by YYSFAYWGQG.

[0481] 3. The isolated monoclonal antibody or antigen-binding fragment thereof of technical solution 1 or 2, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region,

[0482] The light chain variable region comprises:

[0483] VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of RSSQSLVHSNGNTYLQ and KSSQSLVHSNGNTYLQ,

[0484] VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of KVSNRFS, and

[0485] VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY;

[0486] and / or,

[0487] The heavy chain variable region comprises:

[0488] VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH,

[0489] VH CDR2 comprising or consisting of an amino acid sequence selected from the group consisting of GIHPGSGGTAYNQKFKG, GIHPGSGGTAYNQKFQG, and GIHPGSGGTAYAQKFQG, and

[0490] VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

[0491] 4. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 3, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region,

[0492] The light chain variable region comprises:

[0493] VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of: RSSQSLVHSNGNTYLQ,

[0494] VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of KVSNRFS, and

[0495] VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY;

[0496] and

[0497] The heavy chain variable region comprises:

[0498] VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH,

[0499] VH CDR2, which comprises or consists of an amino acid sequence selected from the group consisting of: GIHPGSGGTAYNQKFKG, and

[0500] VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

[0501] 5. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 3, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region,

[0502] The light chain variable region comprises:

[0503] VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of: KSSQSLVHSNGNTYLQ,

[0504] VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of KVSNRFS, and

[0505] VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY;

[0506] and

[0507] The heavy chain variable region comprises:

[0508] VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH,

[0509] VH CDR2, which comprises or consists of an amino acid sequence selected from the group consisting of: GIHPGSGGTAYAQKFQG, and

[0510] VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

[0511] 6. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 3, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region,

[0512] The light chain variable region comprises:

[0513] VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of: RSSQSLVHSNGNTYLQ,

[0514] VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of KVSNRFS, and

[0515] VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY;

[0516] and

[0517] The heavy chain variable region comprises:

[0518] VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH,

[0519] VH CDR2 comprises or consists of an amino acid sequence selected from the group consisting of: GIHPGSGGTAYNQKFQG, and

[0520] VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

[0521] 7. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 6, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence having at least 80%, 85%, at least 90%, at least 95% or higher sequence identity with SEQ ID NO: 11;

[0522] and / or

[0523] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 31 or an amino acid sequence having at least 80%, 85%, at least 90%, at least 95% or higher sequence identity with SEQ ID NO: 31.

[0524] 8. The isolated monoclonal antibody or antigen-binding fragment thereof of technical solution 7, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region,

[0525] The light chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 11, 15, 19, 23 and 27;

[0526] and / or

[0527] The heavy chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 31, 35, 39, 43 and 47.

[0528] 9. The isolated monoclonal antibody or antigen-binding fragment thereof of technical solution 7 or 8, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region,

[0529] wherein the light chain variable region and the heavy chain variable region respectively comprise or consist of an amino acid sequence selected from any one of the following combinations: SEQ ID NO: 11 and SEQ ID NO: 31, SEQ ID NO: 15 and SEQ ID NO: 35, SEQ ID NO: 15 and SEQ ID NO: 39, SEQ ID NO: 15 and SEQ ID NO: 43, SEQ ID NO: 15 and SEQ ID NO: 47, SEQ ID NO: 19 and SEQ ID NO: 39, SEQ ID NO: 19 and SEQ ID NO: 43, SEQ ID NO: 19 and SEQ ID NO: 47, SEQ ID NO: 23 and SEQ ID NO: 35, SEQ ID NO: 23 and SEQ ID NO: 39, SEQ ID NO: 23 and SEQ ID NO: 43, SEQ ID NO: 23 and SEQ ID NO: 47, SEQ ID NO: 27 and SEQ ID NO: 39, SEQ ID NO: 27 and SEQ ID NO: 43, and SEQ ID NO: 27 and SEQ ID NO: 47.

[0530] 10. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 9,

[0531] The monoclonal antibody comprises a heavy chain constant region; optionally, the monoclonal antibody comprises a heavy chain constant region comprising or consisting of the following amino acid sequence: SEQ ID NO: 51;

[0532] and / or

[0533] The monoclonal antibody comprises a light chain constant region; optionally, the monoclonal antibody comprises a light chain constant region comprising or consisting of the following amino acid sequence: SEQ ID NO: 52.

[0534] 11. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 10, wherein the monoclonal antibody comprises a heavy chain and a light chain,

[0535] The heavy chain comprises a heavy chain variable region and a heavy chain constant region, the heavy chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 31, 35, 39, 43 and 47, and the heavy chain constant region comprises or consists of the following amino acid sequence: SEQ ID NO: 51; and / or

[0536] The light chain comprises a light chain variable region and a light chain constant region, wherein the light chain variable region comprises an amino acid sequence selected from any one of the following or consists of an amino acid sequence: SEQ ID NOs: 11, 15, 19, 23 and 27, and the light chain constant region comprises the following amino acid sequence or consists of an amino acid sequence: SEQ ID NO: 52.

[0537] 12. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 11, wherein the monoclonal antibody comprises a heavy chain and a light chain,

[0538] The heavy chain comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 58, 59, 60, 61 and 62; and

[0539] The light chain comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 53, 54, 55, 56 and 57.

[0540] 13. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 12, wherein the monoclonal antibody comprises a heavy chain and a light chain, wherein the heavy chain and the light chain respectively comprise or consist of an amino acid sequence selected from any one of the following combinations: SEQ ID NO: 58 and SEQ ID NO: 53, SEQ ID NO: 59 and SEQ ID NO: 54, SEQ ID NO: 60 and SEQ ID NO: 54, SEQ ID NO: 61 and SEQ ID NO: 54, SEQ ID NO: 62 and SEQ ID NO: 54, SEQ ID NO: 60 and SEQ ID NO: 55, SEQ ID NO: 61 and SEQ ID NO: 55, SEQ ID NO: 62 and SEQ ID NO: 55, SEQ ID NO: 59 and SEQ ID NO: 56, SEQ ID NO: 60 and SEQ ID NO: 56, SEQ ID NO: 61 and SEQ ID NO: 56, SEQ ID NO: 62 and SEQ ID NO: 56, SEQ ID NO: 60 and SEQ ID NO: 57, SEQ ID NO: 61 and SEQ ID NO: 57. NO:57, and SEQ ID NO:62 and SEQ ID NO:57.

[0541] 14. The isolated monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 13,

[0542] wherein all of the monoclonal antibodies are capable of binding to GPC3 protein in vitro with an EC50 of less than 1 nM; and / or

[0543] The monoclonal antibody can bind to the GPC3 protein on the surface of HepG2 cells with an EC50 of less than 5 nM.

[0544] 15. An isolated nucleic acid molecule encoding the monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 14; or

[0545] The nucleic acid molecule comprises a nucleotide sequence selected from any one of the following or consists of a nucleotide sequence: SEQ ID NOs: 1, 2, 3, 4 and 5, and / or the nucleic acid molecule comprises a nucleotide sequence selected from any one of the following or consists of a nucleotide sequence: SEQ ID NOs: 6, 7, 8, 9 and 10; or

[0546] The nucleic acid molecule comprises or consists of a nucleotide sequence selected from any one of the following combinations: SEQ ID NO: 1 and SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 2, SEQ ID NO: 8 and SEQ ID NO: 2, SEQ ID NO: 9 and SEQ ID NO: 2, SEQ ID NO: 10 and SEQ ID NO: 2, SEQ ID NO: 8 and SEQ ID NO: 3, SEQ ID NO: 9 and SEQ ID NO: 3, SEQ ID NO: 10 and SEQ ID NO: 3, SEQ ID NO: 7 and SEQ ID NO: 4, SEQ ID NO: 8 and SEQ ID NO: 4, SEQ ID NO: 9 and SEQ ID NO: 4, SEQ ID NO: 10 and SEQ ID NO: 4, SEQ ID NO: 8 and SEQ ID NO: 5, SEQ ID NO: 9 and SEQ ID NO: 5, and SEQ ID NO: 10 and SEQ ID NO: 5.

[0547] 16. The isolated nucleic acid molecule of technical solution 15, wherein the nucleic acid molecule is operably linked to an expression regulatory sequence.

[0548] 17. An expression vector comprising the nucleic acid molecule of technical solution 15 or 16.

[0549] 18. A host cell comprising the nucleic acid molecule of technical solution 15 or 16 or the expression vector of technical solution 17.

[0550] 19. A hybridoma cell expressing the monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 14.

[0551] 20. An antibody drug conjugate of the following formula:

[0552] Ab-LD, where:

[0553] The symbol "Ab" represents at least one of the aforementioned monoclonal antibodies of the present invention or an antigen-binding fragment thereof;

[0554] The symbol "L" represents a linker that connects the antibody portion and the partner molecule; and

[0555] The symbol “D” represents the partner molecule;

[0556] or

[0557] Ab-(LD)p, where:

[0558] The symbol "Ab" represents at least one of the aforementioned monoclonal antibodies of the present invention or an antigen-binding fragment thereof;

[0559] The symbol “L” represents a linker connecting the antibody portion and the partner molecule;

[0560] The symbol "D" represents a partner molecule; and

[0561] The symbol "p" represents the number of linker / partner molecules (preferably drug cargo) conjugated to the aforementioned monoclonal antibody or antigen-binding fragment thereof of the present invention; alternatively, p is selected from the following values: 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.8, 7.9, 8.1 .7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, and 8.0.

[0562] 21. The antibody-drug conjugate of claim 20, wherein the linker is selected from the group consisting of vc, mc-GGFG, AcLysvc, mc, MalPeg6, m(H20)c, and m(H20)cvc; and / or the linker is cleavable.

[0563] 22. The antibody drug conjugate of technical solution 20 or 21, wherein

[0564] The partner molecule is a drug payload, and the drug payload is a therapeutic molecule; optionally, the drug payload is selected from the group consisting of a cytotoxic agent, a cytostatic agent, an immunomodulatory agent, and a chemotherapeutic agent; optionally, the drug payload is selected from the group consisting of MMAE, MMAF, DM1, DM4, Dxd, SN-38, Topotecan and its derivatives, Exatecan and its derivatives, Belotecan and its derivatives, Camptothecin, Calichemicin, and PBD; or

[0565] The partner molecule is a labeling molecule; optionally, the labeling molecule is selected from the group consisting of a radioactive label (eg, an isotope), a fluorescent label (eg, a fluorescent dye), a chemical substance, and a detectably modified enzyme and tag.

[0566] 23. The antibody-drug conjugate according to any one of technical solutions 20 to 22, wherein the monoclonal antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region respectively comprise or consist of the amino acid sequences shown in any combination of the following: SEQ ID NO: 23 and SEQ ID NO: 47;

[0567] Preferably, the monoclonal antibody comprises a heavy chain and a light chain, wherein the heavy chain and the light chain respectively comprise or consist of the amino acid sequences shown in the following combination: SEQ ID NO: 62 and SEQ ID NO: 56;

[0568] wherein the linker is mc-GGFG; and

[0569] The drug loading is Dxd, p is 3.5 to 8.0.

[0570] 24. A pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 14 or the antibody-drug conjugate according to any one of technical solutions 20 to 23, and optionally a pharmaceutically acceptable carrier.

[0571] 25. Use of the monoclonal antibody or antigen-binding fragment thereof of any one of technical solutions 1-14 or the antibody-drug conjugate of any one of technical solutions 20-23 in the preparation of a pharmaceutical composition; optionally, the pharmaceutical composition is used to treat malignant tumors, prevent and / or treat malignant tumor metastasis or recurrence in patients; optionally, the pharmaceutical composition is used to detect the presence of malignant tumors in patients; optionally, the pharmaceutical composition is used to prognose the recurrence or progression of malignant tumors in patients.

[0572] 26. A method for treating a malignant tumor, preventing and / or treating the metastasis or recurrence of a malignant tumor in a patient, the method comprising administering to the patient an effective amount of the monoclonal antibody or antigen-binding fragment thereof of any one of technical solutions 1-14, the antibody-drug conjugate of any one of technical solutions 20-23, or the pharmaceutical composition of technical solution 24.

[0573] 27. The method of technical solution 26, wherein the malignant tumor is selected from breast cancer, colorectal cancer, pancreatic cancer, prostate cancer, liver cancer, lung cancer (small cell lung cancer) and gastric cancer.

[0574] 28. The method of technical solution 26 or 27 also includes administering other anti-tumor treatments to the patient, such as chemotherapy agents, antibodies targeting other tumor-specific antigens, or radiotherapy.

[0575] 29. A method for detecting the presence of tumor cells in a biological sample, comprising:

[0576] a) contacting the biological sample with the monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 14;

[0577] b) detecting the binding of the monoclonal antibody or antigen-binding fragment thereof to the target antigen in the biological sample,

[0578] Detection of the binding indicates the presence of tumor cells in the biological sample.

[0579] 30. A method of detecting the presence of a malignant tumor in a patient, comprising:

[0580] a) contacting a biological sample obtained from the patient with the monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 14;

[0581] b) detecting binding of the monoclonal antibody or antigen-binding fragment thereof to a target antigen in the biological sample, wherein detection of the binding indicates the presence of a malignant tumor in the patient.

[0582] 31. A method for prognosing recurrence or progression of a malignant tumor in a patient, the method comprising:

[0583] (a) isolating a biological sample comprising tumor cells from the patient;

[0584] (b) contacting the biological sample containing tumor cells with the monoclonal antibody or antigen-binding fragment thereof according to any one of technical solutions 1 to 14; and

[0585] (c) identifying the presence of tumor cells that bind to the monoclonal antibody or antigen-binding fragment thereof,

[0586] The recurrence or progression of the malignancy in said patient is thereby prognosed.

[0587] 32. The method of technical solution 31, wherein the progression of the malignant tumor comprises the metastasis of the malignant tumor in the patient.

[0588] 33. The method of technical solution 31 or 32, wherein the biological sample is selected from the following: a blood sample, a tissue sample, and a lymph sample.

[0589] 34. The method of any one of technical solutions 31-33, wherein the malignant tumor is selected from breast cancer, colorectal cancer, pancreatic cancer, prostate cancer, liver cancer, lung cancer (small cell lung cancer) and gastric cancer.

[0590] 35. A method for producing a monoclonal antibody or an antigen-binding fragment thereof targeting human tumor cells expressing GPC3, comprising:

[0591] (i) culturing the host cell of technical solution 18 under conditions suitable for expression of the nucleic acid molecule or expression vector, and

[0592] (ii) isolating and purifying the antibody or antigen-binding fragment thereof expressed by the nucleic acid molecule or expression vector.

Claims

1. A monoclonal antibody or an antigen-binding fragment thereof targeting GPC3, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, The light chain variable region comprises: VL CDR1 comprises the amino acid sequence of SEQ ID NO: 12 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 12, VL CDR2 comprising the amino acid sequence shown in SEQ ID NO: 13 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 13, and VL CDR3 comprising the amino acid sequence of SEQ ID NO: 14, or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted, or added relative to SEQ ID NO: 14; and / or, The heavy chain variable region comprises: VH CDR1 comprising the amino acid sequence of SEQ ID NO: 32 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 32, VH CDR2 comprising the amino acid sequence shown in SEQ ID NO: 33 or an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO: 33, and VH CDR3 comprising the amino acid sequence of SEQ ID NO: 34 or comprising an amino acid sequence having 1 or 2 amino acid residues substituted, deleted or added relative to SEQ ID NO:

34.

2. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, The light chain variable region comprises: VL CDR1 comprises or consists of the amino acid sequence represented by X1SSQSLVHSNGNTYLQ, The symbol X1 represents: - aliphatic amino acids; - any one of the following amino acids: alanine, valine, leucine, isoleucine, methionine, aspartic acid, glutamic acid, lysine, arginine, glycine, serine, threonine, cysteine, asparagine and glutamine; optionally: alanine or asparagine; - any one of the following amino acids: lysine, arginine and histidine; or - lysine (K) or arginine (R); VL CDR2, which comprises or consists of the amino acid sequence shown in KVSNRFS, and VL CDR3, which comprises or consists of the amino acid sequence represented by CSQSIHVPY; and / or The heavy chain variable region comprises: VH CDR1 comprises or consists of the amino acid sequence shown in DYEMH, VH CDR2 comprises or consists of the amino acid sequence shown in GIHPGSGGTAYX2QKFX3G, The symbol X2 represents: - aliphatic amino acids; - any one of the following amino acids: alanine, valine, leucine, isoleucine, methionine, aspartic acid, glutamic acid, lysine, arginine, glycine, serine, threonine, cysteine, asparagine and glutamine; or - alanine (A) or asparagine (N), The symbol X3 represents: - aliphatic amino acids; - any one of the following amino acids: alanine, valine, leucine, isoleucine, methionine, aspartic acid, glutamic acid, lysine, arginine, glycine, serine, threonine, cysteine, asparagine and glutamine; or - lysine (K) or glutamine (Q), and VH CDR3 comprises or consists of the amino acid sequence represented by YYSFAYWGQG.

3. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 2, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, The light chain variable region comprises: VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of: RSSQSLVHSNGNTYLQ and KSSQSLVHSNGNTYLQ, VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of KVSNRFS, and VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY; and / or, The heavy chain variable region comprises: VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH, VH CDR2 comprises or consists of an amino acid sequence selected from the group consisting of GIHPGSGGTAYNQKFKG, GIHPGSGGTAYNQKFQG, and GIHPGSGGTAYAQKFQG, and VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

4. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 3, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, The light chain variable region comprises: VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of: RSSQSLVHSNGNTYLQ, VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of: KVSNRFS, and VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY; and The heavy chain variable region comprises: VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH, VH CDR2, which comprises or consists of an amino acid sequence selected from the group consisting of: GIHPGSGGTAYNQKFKG, and VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

5. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 4, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, The light chain variable region comprises: VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of: KSSQSLVHSNGNTYLQ, VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of: KVSNRFS, and VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY; and The heavy chain variable region comprises: VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH, VH CDR2 comprises or consists of an amino acid sequence selected from the group consisting of: GIHPGSGGTAYAQKFQG, and VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

6. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 5, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, The light chain variable region comprises: VL CDR1 comprises or consists of an amino acid sequence selected from the group consisting of: RSSQSLVHSNGNTYLQ, VL CDR2 comprises or consists of an amino acid sequence selected from the group consisting of: KVSNRFS, and VL CDR3, which comprises or consists of an amino acid sequence selected from the group consisting of: CSQSIHVPY; and The heavy chain variable region comprises: VH CDR1, which comprises or consists of an amino acid sequence selected from the group consisting of: DYEMH, VH CDR2 comprises or consists of an amino acid sequence selected from the group consisting of: GIHPGSGGTAYNQKFQG, and VH CDR3 comprises or consists of an amino acid sequence selected from the group consisting of: YYSFAYWGQG.

7. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 1 , wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising the amino acid sequence of SEQ ID NO: 11 or an amino acid sequence having at least 80%, 85%, at least 90%, at least 95% or greater sequence identity to SEQ ID NO: 11; and / or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 31 or an amino acid sequence having at least 80%, 85%, at least 90%, at least 95% or higher sequence identity with SEQ ID NO:

31.

8. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 7, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, The light chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 11, 15, 19, 23 and 27; and / or The heavy chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 31, 35, 39, 43 and 47.

9. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 7 or 8, wherein the monoclonal antibody comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region respectively comprise or consist of an amino acid sequence selected from any one of the following combinations: SEQ ID NO: 11 and SEQ ID NO: 31, SEQ ID NO: 15 and SEQ ID NO: 35, SEQ ID NO: 15 and SEQ ID NO: 39, SEQ ID NO: 15 and SEQ ID NO: 43, SEQ ID NO: 15 and SEQ ID NO: 47, SEQ ID NO: 19 and SEQ ID NO: 39, SEQ ID NO: 19 and SEQ ID NO: 43, SEQ ID NO: 19 and SEQ ID NO: 47, SEQ ID NO: 23 and SEQ ID NO: 35, SEQ ID NO: 23 and SEQ ID NO: 39, SEQ ID NO: 23 and SEQ ID NO: 43, SEQ ID NO: 23 and SEQ ID NO: 47, SEQ ID NO: 27 and SEQ ID NO: 39, SEQ ID NO: 27 and SEQ ID NO: 43, and SEQ ID NO: 27 and SEQ ID NO:

47.

10. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 1 or 9, The monoclonal antibody comprises a heavy chain constant region; optionally, the monoclonal antibody comprises a heavy chain constant region comprising or consisting of the following amino acid sequence: SEQ ID NO: 51; and / or The monoclonal antibody comprises a light chain constant region; optionally, the monoclonal antibody comprises a light chain constant region comprising or consisting of the following amino acid sequence: SEQ ID NO:

52.

11. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 10, wherein the monoclonal antibody comprises a heavy chain and a light chain, The heavy chain comprises a heavy chain variable region and a heavy chain constant region, the heavy chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 31, 35, 39, 43 and 47, and the heavy chain constant region comprises or consists of the following amino acid sequence: SEQ ID NO: 51; and / or The light chain comprises a light chain variable region and a light chain constant region, wherein the light chain variable region comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 11, 15, 19, 23 and 27, and the light chain constant region comprises or consists of the following amino acid sequence: SEQ ID NO:

52.

12. The isolated monoclonal antibody or antigen-binding fragment thereof of claim 11, wherein the monoclonal antibody comprises a heavy chain and a light chain, The heavy chain comprises or consists of an amino acid sequence selected from any one of the following: SEQ ID NOs: 58, 59, 60, 61 and 62; and The light chain comprises an amino acid sequence selected from any one of the following or consists of the amino acid sequence: SEQ ID NOs: 53, 54, 55, 56 and 57.

13. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 12, wherein the monoclonal antibody comprises a heavy chain and a light chain, wherein the heavy chain and the light chain each comprise or consist of an amino acid sequence selected from any one of the following combinations: SEQ ID NO:58 and SEQ ID NO:53, SEQ ID NO:59 and SEQ ID NO:54, SEQ ID NO:60 and SEQ ID NO:54, SEQ ID NO:61 and SEQ ID NO:54, SEQ ID NO:62 and SEQ ID NO:54, SEQ ID NO:60 and SEQ ID NO:55, SEQ ID NO:61 and SEQ ID NO:55, SEQ ID NO:62 and SEQ ID NO:55, SEQ ID NO:59 and SEQ ID NO:56, SEQ ID NO:60 and SEQ ID NO:56, SEQ ID NO:61 and SEQ ID NO:56, SEQ ID NO:62 and SEQ ID NO:56, SEQ ID NO:60 and SEQ ID NO:57, SEQ ID NO:61 and SEQ ID NO:57, and SEQ ID NO:62 and SEQ ID NO:57; Preferably, the heavy chain and the light chain respectively comprise or consist of the amino acid sequences shown in the following combination: SEQ ID NO: 62 and SEQ ID NO:

57.

14. The isolated monoclonal antibody or antigen-binding fragment thereof according to claim 1 or 7, wherein the monoclonal antibody is capable of binding to GPC3 protein in vitro with an EC50 of less than 1 nM; and / or The monoclonal antibody can bind to the GPC3 protein on the surface of HepG2 cells with an EC50 of less than 5 nM.

15. An antibody drug conjugate of the following formula: Ab-(LD)p, where: The symbol "Ab" represents at least one monoclonal antibody or antigen-binding fragment portion thereof according to any one of claims 1 to 14; The symbol "L" represents a linker connecting the antibody portion and the partner molecule; The symbol "D" represents the partner molecule; and The symbol "p" represents the amount of drug cargo conjugated to at least one portion of the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, wherein p is selected from the following values: 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4. 5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, and 8.

0.

16. An antibody-drug conjugate according to technical solution 20, wherein the linker is selected from the following: vc, mc-GGFG, AcLysvc, mc, MalPeg6, m(H20)c and m(H20)cvc; and / or the linker is cleavable.

17. The antibody drug conjugate according to claim 15 or 16, wherein The drug payload is selected from the group consisting of cytotoxic agents, cytostatic agents, immunomodulators, and chemotherapeutic agents; preferably, the drug payload is selected from the group consisting of MMAE, MMAF, DM1, DM4, Dxd, SN-38, Topotecan and its derivatives, Exatecan and its derivatives, Belotecan and its derivatives, Camptothecin, Calicheamicin, and PBD.

18. The antibody-drug conjugate according to any one of technical solutions 15 to 17, wherein the monoclonal antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region respectively comprise or consist of the amino acid sequences shown in any combination of the following: SEQ ID NO: 23 and SEQ ID NO: 47; Preferably, the monoclonal antibody comprises a heavy chain and a light chain, wherein the heavy chain and the light chain respectively comprise or consist of the amino acid sequences shown in the following combination: SEQ ID NO: 62 and SEQ ID NO: 56; wherein the linker is mc-GGFG; and The drug loading is Dxd, p is 3.5 to 8.

0.

19. A pharmaceutical composition comprising the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 or the antibody-drug conjugate according to any one of claims 15 to 18, and optionally a pharmaceutically acceptable carrier.

20. Use of the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 14 or the antibody-drug conjugate according to any one of claims 15 to 18 in the preparation of a pharmaceutical composition; optionally, the pharmaceutical composition is used to treat a malignant tumor, prevent and / or treat metastasis or recurrence of a malignant tumor in a patient; optionally, the pharmaceutical composition is used to detect the presence of a malignant tumor in a patient; optionally, the pharmaceutical composition is used to prognose the recurrence or progression of a malignant tumor in a patient.

21. A method for treating a malignant tumor, preventing and / or treating metastasis or recurrence of a malignant tumor in a patient, the method comprising administering to the patient an effective amount of the monoclonal antibody or antigen-binding fragment thereof according to any one of claims 1 to 14, the antibody-drug conjugate according to any one of claims 15 to 18, or the pharmaceutical composition of technical solution 19.

22. The method of claim 21, wherein the malignant tumor is selected from the group consisting of breast cancer, colorectal cancer, pancreatic cancer, prostate cancer, liver cancer, lung cancer (small cell lung cancer), and gastric cancer.